Cryoport (CYRX) 10-K 25 Jun 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Mar. 31, 2014	Jun. 13, 2014	Sep. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'Cryoport, Inc.	'	'
Entity Central Index Key	'0001124524	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Mar-14	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Current Fiscal Year End Date	'--03-31	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$27,964,500
Entity Common Stock, Shares Outstanding	'	59,987,846	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Mar. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$369,581	$563,104
Accounts receivable, net of allowance for doubtful accounts of $24,600 and $8,700, respectively	515,825	217,097
Inventories	29,703	39,212
Other current assets	196,505	138,892
Total current assets	1,111,614	958,305
Property and equipment, net	408,892	505,485
Intangible assets, net	180,086	272,263
Deposits and other assets	9,358	19,744
Total assets	1,709,950	1,755,797
Current liabilities:	'	'
Accounts payable and other accrued expenses	579,678	858,709
Accrued compensation and related expenses	454,288	217,432
Convertible debentures payable and accrued interest, net of discount of $184,750 in 2014	1,622,359	1,304,419
Current portion of related party notes payable	1,358,120	96,000
Derivative liabilities	'	20,848
Total current liabilities	4,014,445	2,497,408
Related party notes payable and accrued interest, net of current portion	'	1,321,664
Total liabilities	4,014,445	3,819,072
Commitments and contingencies	'	'
Stockholders' (Deficit) Equity:	'	'
Preferred stock, $0.001 par value, 2,500,000 shares authorized, none issued and outstanding	'	'
Common stock, $0.001 par value; 250,000,000 shares authorized; 59,979,954 and 37,760,628 issued and outstanding at March 31, 2014 and 2013, respectively	59,980	37,761
Additional paid-in capital	83,512,399	64,210,412
Accumulated deficit	-85,876,874	-66,311,448
Total stockholders' deficit	-2,304,495	-2,063,275
Total liabilities and stockholders' deficit	$1,709,950	$1,755,797

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Consolidated Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts receivable	$24,600	$8,700
Discount on convertible debentures, current	$184,750	$0
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	2,500,000	2,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	59,979,954	37,760,628
Common stock, shares outstanding	59,979,954	37,760,628

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Consolidated Statements of Operations [Abstract]	'	'
Revenues	$2,659,943	$1,100,539
Cost of revenues	2,222,988	1,587,823
Gross margin (loss)	436,955	-487,284
Operating costs and expenses:	'	'
Selling, general and administrative	5,106,219	5,411,728
Research and development	409,111	425,446
Total operating costs and expenses	5,515,330	5,837,174
Loss from operations	-5,078,375	-6,324,458
Other (expense) income:	'	'
Debt conversion expense	-13,713,767	'
Interest expense	-784,454	-72,861
Other expense, net	-8,078	'
Change in fair value of derivatives	20,848	16,486
Loss before provision for income taxes	-19,563,826	-6,380,833
Provision for income taxes	-1,600	-1,600
Net loss	($19,565,426)	($6,382,433)
Net loss per common share - basic and diluted	($0.40)	($0.17)
Weighted average shares outstanding - basic and diluted	48,850,513	37,760,628

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' (Deficit) Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balance at Mar. 31, 2012	$3,729,520	'	$37,761	$63,620,774	($59,929,015)
Balance, shares at Mar. 31, 2012	'	'	37,760,628	'	'
Net loss	-6,382,433	'	'	'	-6,382,433
Offering costs in connection with the February 2012 private placement offering	-103,542	'	'	-103,542	'
Stock-based compensation expense	693,180	'	'	693,180	'
Balance at Mar. 31, 2013	-2,063,275	'	37,761	64,210,412	-66,311,448
Balance, shares at Mar. 31, 2013	'	'	37,760,628	'	'
Net loss	-19,565,426	'	'	'	-19,565,426
Stock-based compensation expense	678,119	'	'	678,119	'
Estimated relative fair value of warrants issued in connection with convertible bridge notes payable	478,229	'	'	478,229	'
Issuance of common stock upon exercise of options and warrants	326,890	'	1,583	325,307	'
Issuance of common stock upon exercise of options and warrants, shares	'	'	1,583,315	'	'
Issuance of common stock units upon conversion of convertible bridge notes and accrued interest	4,127,201	'	20,636	4,106,565	'
Issuance of common stock units upon conversion of convertible bridge notes and accrued interest, shares	'	'	20,636,011	'	'
Induced debt conversion expense	13,713,767	'	'	13,713,767	'
Balance at Mar. 31, 2014	($2,304,495)	'	$59,980	$83,512,399	($85,876,874)
Balance, shares at Mar. 31, 2014	'	'	59,979,954	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flows From Operating Activities:	'	'
Net loss	($19,565,426)	($6,382,433)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	311,590	393,959
Amortization of debt discount and deferred financing costs	678,915	17,514
Stock-based compensation expense	678,119	693,180
Change in fair value of derivative instruments	-20,848	-16,486
Loss on write-off of intangible assets	'	17,046
Loss on disposal of cryogenic shippers	16,066	51,033
Reserve for bad debt	24,876	'
Debt conversion expense	13,713,767	'
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	-323,604	-70,973
Inventories	9,509	12,542
Other assets	-26,588	34,912
Accounts payable and other accrued expenses	-221,929	443,568
Accrued compensation and related expenses	236,856	-18,564
Accrued interest	108,038	39,558
Net cash used in operating activities	-4,380,659	-4,785,144
Cash Flows From Investing Activities:	'	'
Purchases of intangible assets	'	-22,482
Purchases of property and equipment	-138,886	-156,200
Net cash used in investing activities	-138,886	-178,682
Cash Flows From Financing Activities:	'	'
Proceeds from exercise of options and warrants	326,890	'
Proceeds from issuance of convertible debt	4,558,301	1,294,500
Repayment of convertible debt	'	-82,800
Repayment of offering and deferred financing costs	-463,169	-206,305
Repayment of related party notes payable	-96,000	-96,000
Net cash provided by financing activities	4,326,022	909,395
Net change in cash and cash equivalents	-193,523	-4,054,431
Cash and cash equivalents - beginning of year	563,104	4,617,535
Cash and cash equivalents - end of year	369,581	563,104
Supplemental Disclosure of Cash Flow Information:	'	'
Cash paid for interest	'	15,676
Cash paid for income taxes	1,600	1,600
Supplemental Disclosure of Non-Cash Investing and Financing Activities:	'	'
Offering costs in connection with equity financing included in accounts payable	'	53,747
Deferred financing costs in connection with convertible debt payable included in accounts payable	30,120	38,475
Release of restricted cash for repayment of convertible debentures payable	'	251,368
Estimated relative fair value of warrants issued in connection with convertible bridge notes payable	478,229	'
Conversion of bridge notes payable and accrued interest into common stock units	$4,127,201	'

Nature_of_the_Business

Nature of the Business	12 Months Ended
	Mar. 31, 2014
Nature of the Business [Abstract]	'
Nature of the Business	'
	Note 1. Nature of the Business
	Cryoport Inc. (the "Company", "Cryoport" or "we") is a Nevada corporation originally incorporated under the name G.T.5-Limited ("GT5") on May 25, 1990. In connection with a Share Exchange Agreement, on March 15, 2005 we changed our name to Cryoport, Inc. and acquired all of the issued and outstanding shares of common stock of Cryoport Systems, Inc., a California corporation, in exchange for 2,410,811 shares of our common stock (which represented approximately 81% of the total issued and outstanding shares of common stock following the close of the transaction). Cryoport Systems, Inc., which was originally formed in 1999 as a California limited liability company, and subsequently reorganized into a California corporation on December 11, 2000, remains the operating company under Cryoport, Inc. We became "publicly held" by the reverse merger with GT5 described above. Over time we have transitioned from being a development company to a fully operational public company, providing cold chain logistics solutions to the biotechnology and life sciences industries, globally.
	Through a combination of purpose-built proprietary packaging, information technologies and specialized logistics knowhow, we provide frozen shipping logistics solutions to the life sciences industry. We view our solutions as disruptive to "older technologies" in that our solutions provide reliable, economic alternatives to existing solutions and services utilized for frozen shipping in life sciences including stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances and other items that require continuous exposure to frozen or cryogenic temperatures.
	Our Cryoport Express® Solutions includes sophisticated cloud-based logistics management software we have branded as the Cryoportal™ which supports the management of the entire shipment process through a single interface, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. The Cryoportal™ provides unique and incisive information dashboards and validation documentation for every shipment. The Cryoportal™ records and retains a fully documented "chain-of-custody" and, at the client's option, "chain-of-condition" for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities are maintained throughout the process. This recorded and archived information allows our customers to meet exacting requirements necessary for scientific work and for regulatory purposes.
	Our Cryoport Express® Solutions also includes our liquid nitrogen dry vapor shippers we have branded as our Cryoport Express® Shippers, which are cost-effective and reusable cryogenic transport containers (patented vacuum flasks) utilizing innovative liquid nitrogen ("LN2") "dry vapor" technology. Cryoport Express® Shippers are International Air Transport Association ("IATA") certified, and validated to maintain stable temperatures of minus 150° C and below for a 10-plus day dynamic shipment period. The Company currently features two Cryoport Express® Shipper models, the Standard Dry Shipper (holding up to 75-2.0 ml vials) and the High Volume Dry Shipper (holding up to 500-2.0 ml vials).
	Amongst our solutions, we offer a "turnkey" solution, which can be accessed through our cloud-based Cryoportal™ or by contacting Cryoport Client Care for order entry. Once the order is placed, we ship a fully charged Cryoport Express® Shipper to the customer who conveniently loads their frozen commodity into the inner chamber of the shipper.  The customer then closes the shipper and reseals the shipping box displaying the recipient's address ("Flap A") for pre-arranged carrier pick up.  Cryoport arranges for the pick-up of the parcel by a shipping service provider for delivery to the customer's intended recipient.  The recipient simply opens the box and shipper and removes the frozen commodity.  The recipient only needs to reseal the box, displaying the nearest Cryoport Operations Center address ("Flap B") and set it out for pre-arranged carrier pick up. The Cryoport Express® Shipper is returned to us for cleaning, quality assurance testing, recharging and reuse.
	In late 2012, we shifted our focus from being a developer of cryogenic shippers and software to being a comprehensive frozen logistics solutions provider to the life sciences industry, which was accomplished by broadening our service offerings. Now, in addition to our "Turn-key Solution", we also provide the following value-added solutions that were developed to address our various clients' needs:
		·	"Customer Staged Solution," under which we supply an inventory of our Cryoport Express® Shippers to our customer, in an uncharged state, enabling our customer (after training/certification) to charge them with liquid nitrogen and use our Cryoportal™ to enter orders with shipping and delivery service providers for the transportation of the package. Once the order is released, our customer services professionals monitor the shipment and the return of the shipper to us for cleaning, quality assurance testing and reuse.
		·	"Customer Managed Solution," a limited customer implemented, solution, whereby we supply our Cryoport Express® Shippers to clients in a fully charged state, but leaving it to the client to manage the shipping, including the selection of the shipping and delivery service provider and the return of the shipper to us. Under this solution, the customer accepts a significant level of the risk for a successful shipment.
		·	"Powered by CryoportSM" is made available to providers of shipping and delivery services who seek to offer a "branded" cryogenic shipping solution as part of their service offerings. By negotiation, this solution can be private labeled as long as "powered by CryoportSM" appears prominently on the offering software interface and prominently on the packaging, which is provided by the client after minimum volume requirements are met.
		·	"Integrated Solution" is our most comprehensive and complex outsourcing solution. It usually involves our management of the entire cryogenic logistics process for our client, including the location of our employees at the client's site to manage the client's cryogenic logistics, in total.
		·	"Life Science Point-of-Care Repository Solution" whereby we supply our Cryoport Express® Shippers to ship and store cryogenically preserved life science products for up to 6 days (or longer periods with substitute Shippers) at a point-of-care site, with the Cryoport Express® Shippers serving as a temporary freezer/repository enabling the efficient distribution of temperature sensitive allogeneic cell-based therapies without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation apparatus. Our customer services professionals monitor each shipment throughout the predetermined process including the shipment's return to Cryoport where the Cryoport Express® Shipper is cleaned, tested for quality assurance and then returned to inventory for reuse.
		·	"Personalized Medicine and Cell-based Immunotherapy Solution" whereby our Cryoport Express® Solutions serves as an enabling technology for the safe manufacture of the rapidly expanding autologous cellular-based immunotherapy market by providing a comprehensive logistics solution for the verified chain of custody and condition transport from, (a) the collection of the patient's cells in a hospital setting, to (b) a central processing facility where they are manufactured into a personalized medicine, to (c) the safe, cryogenically preserved return of these irreplaceable cells to a point-of-care treatment facility.  The Cryoport Express® Shippers can then serve as a temporary freezer/repository to allow the efficient distribution of this personalized medicine to patients when and where they need it most without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation apparatus. Our customer services professionals monitor each shipment throughout the predetermined process including the shipment's return to Cryoport where the Cryoport Express® Shipper is cleaned, tested for quality assurance and then returned to inventory for reuse.
	One of our distribution partners is Federal Express Corporation ("FedEx"). We have an agreement with FedEx to provide frozen shipping logistics services through the combination of our purpose-built proprietary technologies and turnkey management processes. FedEx markets and sells Cryoport's services for frozen temperature-controlled cold chain transportation as its FedEx® Deep Frozen Shipping Solution on a non-exclusive basis and at its sole expense. During fiscal year 2013, the Company worked closely with FedEx to further align its sales efforts and accelerate penetration within FedEx's life sciences customer base through improved processes, sales incentives, joint customer calls and more frequent communication at the sales and executive level. In addition, FedEx has developed a FedEx branded version of the CryoportalTM software platform, which is "powered by Cryoport" for use by FedEx and its customers giving them access to the full capabilities of our logistics management platform.
	In January 2013, we entered into a master agreement ("FedEx Agreement") with FedEx renewing these services and providing FedEx with a non-exclusive license and right to use a customized version of our CryoportalTM for the management of shipments made by FedEx customers. The FedEx Agreement became effective on January 1, 2013 and, unless sooner terminated as provided in the FedEx Agreement, expires on December 31, 2015.
	Pursuant to an agreement with DHL Express (USA), Inc. ("DHL"), DHL biotechnology and life science customers have direct access to our cloud-based order entry and tracking portal to order Cryoport Express® Shippers and receive preferred DHL shipping rates. The agreement covers DHL shipping discounts that may be used to support our customers using our Cryoport Express® Solutions. In connection with the agreement, we have integrated our proprietary CryoportalTM to DHL's tracking and billing systems to provide DHL biotechnology and life science customers with a seamless way ("powered by Cryoport") of shipping their critical biological material worldwide.
	In December 2012, we signed an agreement with Pfizer Inc. relating to Zoetis Inc. (formerly the animal health business unit of Pfizer Inc.) pursuant to which we were engaged to manage frozen shipments of a key poultry vaccine. Under this arrangement, the Company is providing on-site logistics personnel and its logistics management platform, the CryoportalTM, to manage shipments from the Zoetis manufacturing site in the United States to domestic customers as well as various international distribution centers. As part of our logistics management services, Cryoport is constantly analyzing shipping data and processes to further streamline Zoetis' logistics, ensuring products arrive at their destinations in specified conditions, on-time and with the optimum uses of resources. The Company manages Zoetis' total fleet of dewar flask shippers used for this purpose, including liquid nitrogen shippers. In July 2013 the agreement was amended to expand Cryoport's scope to manage all logistics of Zoetis' key frozen poultry vaccine to all Zoetis' international distribution centers as well as all domestic shipments of this vaccine. In October 2013, the agreement was further amended to further expand Cryoport's services to include the logistics management for a second poultry vaccine.
	In February 2014, we entered into a services agreement with Liventa Bioscience, Inc. ("Liventa"), a privately-held, commercial stage biotechnology company focused on cell-based, advanced biologics in the orthopedic industry. Under this agreement, Liventa will be using Cryoport Express® Solutions for the logistics of its cell-based therapies requiring cryogenic temperatures and also provide Cryoport Express® Solutions to other biologics suppliers within the orthopedic arena. The agreement combines Cryoport's proprietary, purpose-built cold chain logistics solutions for cell-based and advanced biologic tissue forms with Liventa's distribution capability to orthopedic care providers. The implementation of Cryoport's solution will eliminate dry ice shipping and related risks of degradation and also eliminate the need for expensive onsite cryogenic freezers for storage of cell-based orthopedic therapies. This will enable Liventa to better serve small or mobile clinics, pharmacies, family practice, and orthopedic specialty care providers. Surgical centers and hospitals will also benefit from better logistics and the elimination of issues surrounding dry ice transport and storage. The agreement has an initial three-year term and may be renewed for consecutive three-year terms. Liventa also agreed to certain performance criteria and the issuance of 150,000 shares of its common stock to Cryoport in exchange for the exclusive right to offer, market and promote Cryoport Express® Solutions for cellular-based therapies requiring cryogenic temperatures for use
	in orthopedic indications in the United States.
	We offer our solutions to companies in the life sciences industry and specific verticals including manufacturers of stem cells and cell lines, diagnostic laboratories, bio-pharmaceuticals, contract research organizations, in-vitro fertilization, cord blood, vaccines, tissue, animal husbandry, and other producers of commodities requiring reliable frozen solutions for logistics problems. These companies operate within heavily regulated environments and as such, changing vendors and distribution practices typically require a number of steps which may include the audit of our facilities, review of our procedures, qualifying us as a vendor, and performing test shipments. This process can take up to nine months or longer to complete prior to a potential customer adopting one or more of the Cryoport Express® Solutions.
	Going Concern
	The consolidated financial statements have been prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. We have sustained operating losses since our inception and have used substantial amounts of working capital in our operations. Further, at March 31, 2014, we had an accumulated deficit of $85.9 million. During the year ended March 31, 2014, we used cash in operations of $4.4 million and had a net loss of $19.6 million, which included a one-time, non-cash debt conversion expense of $13.7 million.
	We expect to continue to incur substantial additional operating losses from costs related to the commercialization of our Cryoport Express® Solutions and do not expect that revenues from operations will be sufficient to satisfy our funding requirements in the near term. We believe that our cash resources at March 31, 2014, additional funds raised subsequent to March 31, 2014 through the current preferred stock offering (see Note 15), together with the revenues generated from our services will be sufficient to sustain our planned operations into the second quarter of fiscal year 2015; however, we must obtain additional capital to fund operations thereafter and for the achievement of sustained profitable operations. These factors raise substantial doubt about our ability to continue as a going concern. We are currently working on funding alternatives in order to secure sufficient operating capital to allow us to continue to operate as a going concern.
	Future capital requirements will depend upon many factors, including the success of our commercialization efforts and the level of customer adoption of our Cryoport Express® Solutions as well as our ability to establish additional collaborative arrangements. We cannot make any assurances that the sales ramp will lead to achievement of sustained profitable operations or that any additional financing will be completed on a timely basis and on acceptable terms or at all. Management's inability to successfully achieve significant revenue increases or implement cost reduction strategies or to complete any other financing will adversely impact our ability to continue as a going concern. To address this issue, the Company is seeking additional capitalization to properly fund our efforts to become a self-sustaining financially viable entity.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 2. Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiary, Cryoport Systems, Inc. All intercompany accounts and transactions have been eliminated.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company's significant estimates include allowances for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, valuation of derivative liabilities and valuation of common stock, warrants and stock options issued for products or services.
	Fair Value of Financial Instruments
	The Company's financial instruments consist of cash and cash equivalents, accounts receivable, related-party notes payable, convertible notes payable, accounts payable and accrued expenses. The carrying value for all such instruments approximates fair value at March 31, 2014 and 2013 due to their short-term nature. The difference between the fair value and recorded values of the related party notes payable is not significant.
	Cash and Cash Equivalents
	The Company considers highly liquid investments with original maturities of 90 days or less to be cash equivalents.
	Concentrations of Credit Risk
	The Company maintains its cash accounts in financial institutions. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") with basic deposit insurance coverage limits up to $250,000 per owner. At March 31, 2014 and 2013, the Company had cash balances of approximately $159,000 and $214,000, respectively, which exceeded the FDIC insurance limit. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.
	Customers
	The Company grants credit to customers within the U.S. and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for a limited number of established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company's ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at March 31, 2014 and 2013 are net of reserves for doubtful accounts of $24,600 and $8,700, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts.
	The majority of the Company's customers are in the biotechnology, pharmaceutical and life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. At March 31, 2014, there was one customer that accounted for 30.6% of net accounts receivable. No other single customer owed us more than 10% of net accounts receivable at March 31, 2014 and 2013. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded our estimates.
	The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During fiscal years 2014 and 2013, the Company had revenues from foreign customers of approximately $434,000 and $161,000, respectively, which constituted approximately 16.3% and 14.6% of total revenues, respectively. For the fiscal year ended March 31, 2014, there was one customer that accounted for 30.8% of net revenues. No other single customer generated over 10% of net revenues during 2014 and 2013.
	Inventories
	The Company's inventories consist of accessories that are sold and shipped to customers along with pay-per-use containers that are not returned to the Company with the containers at the culmination of the customer's shipping cycle. Inventories are stated at the lower of cost or current estimated market value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, and based on the evaluation, records adjustments to reflect inventories at its net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company's products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company's forecasts of market conditions, industry trends, competition and other factors.
	Property and Equipment
	The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company's arrangements are similar to the accounting standard for leases since they convey the right to use the container over a period of time. The Company retains the title to the containers and provides its customers the use of the container for a specific shipping cycle. At the culmination of the customer's shipping cycle, the container is returned to the Company. As a result, the Company classifies the containers as fixed assets for the per-use container program.
	Property and equipment are recorded at cost. Cryogenic shippers, which comprise of 89% and 87% of the Company's net property and equipment balance at March 31, 2014 and 2013, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Equipment acquired under capital leases is amortized over the estimated useful life of the assets or term of the lease, whichever is shorter and included in depreciation expense.
	Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in current operations.
	Intangible Assets
	Intangible assets are comprised of patents and trademarks and software development costs. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years. The Company capitalizes certain costs related to software developed for internal use. Software development costs incurred during the preliminary or maintenance project stages are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized using the straight-line method over the estimated useful life of the software, which is five years. Capitalized costs include purchased materials and costs of services including the valuation of warrants issued to consultants.
	Long-lived Assets
	If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets' carrying value, and accordingly, we have not recognized any impairment losses through March 31, 2014.
	Deferred Financing Costs
	Deferred financing costs represent costs incurred in connection with the issuance of the convertible notes payable and private equity financing. Deferred financing costs related to the issuance of debt are being amortized over the term of the financing instrument using the effective interest method while deferred financing costs from equity financings are netted against the gross proceeds received from the equity financings.
	In connection with the 5% Bridge Notes, during the third and fourth quarter of fiscal 2014, the Company incurred financing costs that have been capitalized and are being amortized over the term of the convertible bridge notes payable using the straight-line method which approximates the effective interest method (see Note 8).
	During the year ended March 31, 2013, the Company incurred $103,542 of offering costs in connection with the private placement that closed in February and March 2012, which were charged to additional paid-in capital and netted against the proceeds received in the private placements. As of March 31, 2013, offering costs of $53,747 related to the private placement were included in accounts payable and accrued expenses in the accompanying consolidated balance sheet.
	Convertible Debentures
	If a conversion feature of conventional convertible debt is not accounted for as a derivative instrument and provides for a rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature ("BCF"). A BCF is recorded by the Company as a debt discount. The convertible debt is recorded net of the discount related to the BCF. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method.
	Derivative Liabilities
	Certain of the Company's issued and outstanding common stock purchase warrants which have exercise price reset features are treated as derivatives for accounting purposes. The common stock purchase warrants were not issued with the intent of effectively hedging any future cash flow, fair value of any asset, liability or any net investment in a foreign operation. The warrants do not qualify for hedge accounting, and as such, all future changes in the fair value of these warrants are recognized currently in earnings until such time as the warrants are exercised, expire or the related rights have been waived. These common stock purchase warrants do not trade in an active securities market, and as such, the Company estimates the fair value of these warrants using the Black-Scholes option pricing model ("Black-Scholes") (see Note 9).
	Income Taxes
	The Company accounts for income taxes under the provision of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 740, Income Taxes , or ASC 740. As of March 31, 2014 and 2013, there were no unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rates.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company's management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company's income tax provision consists of state minimum taxes.
	The Company's policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets at March 31, 2014 and 2013, respectively and has not recognized interest and/or penalties in the consolidated statement of operations for the years ended March 31, 2014 and 2013. The Company is subject to taxation in the U.S. and various state jurisdictions. As of March 31, 2014, the Company is no longer subject to U.S. federal examinations for years before 2010 and for California franchise and income tax examinations for years before 2009. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions.
	Revenue Recognition
	The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company's arrangements are similar to the accounting standard for leases since they convey the right to use the containers over a period of time. The Company retains title to the containers and provides its customers the use of the container for a specified shipping cycle. At the culmination of the customer's shipping cycle, the container is returned to the Company.
	The Company recognizes revenue for the use of the shipper at the time of the delivery of the shipper to the end user of the enclosed materials, and at the time that collectability is reasonably certain. Revenue is based on gross net of discounts and allowances.
	The Company also provides logistics support and management to some customers, which may include onsite logistics personnel. Revenue is recognized for these services as services are rendered and at the time that collectability is reasonably certain.
	Accounting for Shipping and Handling Revenue, Fees and Costs
	The Company classifies amounts billed for shipping and handling as revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations.
	Research and Development Expenses
	Expenditures relating to research and development are expensed in the period incurred.
	Stock-based Compensation
	The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at grant date using Black-Scholes and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.
	Since stock-based compensation is recognized only for those awards that are ultimately expected to vest, the Company has applied an estimated forfeiture rate to unvested awards for the purpose of calculating compensation cost. These estimates will be revised, if necessary, in future periods if actual forfeitures differ from estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs. The estimated forfeiture rates at March 31, 2014 and 2013 was zero as the Company has not had a significant history of forfeitures and does not expect significant forfeitures in the future.
	Cash flows from the tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options or warrants are classified as financing cash flows. Due to the Company's loss position, there were no such tax benefits during years ended March 31, 2014 and 2013.
	The Company uses Black-Scholes to estimate the fair value of stock-based awards. The determination of fair value using Black-Scholes is affected by the Company's stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.
	The Company's stock-based compensation plans are discussed further in Note 12.
	Equity Instruments Issued to Non-Employees for Acquiring Goods or Services
	Issuances of the Company's common stock for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a "performance commitment" which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.
	Basic and Diluted Net Income (Loss) Per Share
	We calculate basic and diluted net income (loss) per share using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for preferred stock dividends (if any) declared during the period. In periods of a net loss position, basic and diluted weighted average shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and other common stock equivalents outstanding during the periods.
	The following shows the amounts used in computing net loss per share for each of the two years in the period ended March 31, 2014:
		Years Ended March 31,
		2014			2013
	Net loss	$	(19,565,426	)	$	(6,382,433	)
	Less:
	Preferred dividends paid in cash or stock		-			-
Loss attributable to Cryoport stockholders	$	(19,565,426	)	$	(6,382,433	)
Weighted average shares issued and outstanding		48,850,513			37,760,628
Basic and diluted net loss per share	$	(0.40	)	$	(0.17	)
The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would have been anti-dilutive:
	Years Ended March 31,
	2014			2013
Stock options		3,458,313			411,762
Warrants		3,221,728			-
		6,680,041			411,762
Segment Reporting
We currently operate in one reportable segment.
Fair Value Measurements
We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Currently we do not have any items classified as Level 2.
Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.
We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values.
The carrying values of our assets and liabilities that are required to be measured at fair value on a recurring basis as of March 31, 2014 and 2013 are classified in the table below in one of the three categories of the fair value hierarchy described below:
	Fair Value Measurements
	Level 1			Level 2			Level 3		Total
31-Mar-13
Liabilities:
Derivative liabilities	$	-		$	-		$	20,848	$	20,848
The following summarizes the activity of Level 3 inputs measured on a recurring basis for the years ended March 31, 2014 and 2013:
	Fair Value Measurements of  Unobservable Inputs (Level 3)
Balance at March 31, 2012	$	37,334
Transfers in / (out) of Level 3		-
Adjustments resulting from a change in fair value of derivative liabilities		(16,486	)
Balance at March 31, 2013		20,848
Transfers in / (out) of Level 3		-
Adjustments resulting from a change in fair value of derivative liabilities		(20,848	)
Balance at March 31, 2014	$	-
The fair value of derivative liabilities were measured on their respective origination dates and at the end of each reporting period using Level 3 inputs. The significant assumptions we use in the calculations under Black-Scholes as of March 31, 2014 and 2013 included an expected term based on the remaining contractual life of the warrants, a risk-free interest rate based upon observed interest rates appropriate for the expected term of the instruments, volatility based on the historical volatility of our common stock, and a zero dividend rate based on our past, current and expected practices of granting dividends on common stock.
Foreign Currency Translation
We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any of the periods presented.
Recent Accounting Pronouncements
In July 2013, the FASB issued ASU No. 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists." ASU 2013-11 provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. This pronouncement is effective for reporting periods beginning on or after January 1, 2013. The adoption of ASU 2011-11 did not have a material impact on the Company's consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers". ASU 2014-09 supersedes the revenue recognition requirements in FASB Topic 605, "Revenue Recognition". The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 will have on our consolidated financial statements.

Inventories

Inventories	12 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Inventories	'
	Note 3. Inventories
	Inventories consist of the following:
		March 31,
		2014		2013
	Raw materials	$	18,283	$	28,533
	Finished goods		11,420		10,679
		$	29,703	$	39,212

Property_and_Equipment

Property and Equipment	12 Months Ended
	Mar. 31, 2014
Property and Equipment [Abstract]	'
Property and Equipment	'
	Note 4. Property and Equipment
	Property and equipment consist of the following:
		March  31,
		2014			2013
	Cryogenic shippers	$	1,037,286		$	962,565
	Furniture and fixtures		30,746			30,746
	Machinery and equipment		386,731			380,526
	Leasehold improvements		30,913			30,913
			1,485,676			1,404,750
	Less accumulated depreciation and amortization		(1,076,784	)		(899,265	)
		$	408,892		$	505,485
	Total depreciation and amortization expense related to property and equipment amounted to $219,400 and $281,700 for the years ended March 31, 2014 and 2013, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2014
Intangible Assets [Abstract]	'
Intangible Assets	'
	Note 5. Intangible Assets
	Intangible assets consist of the following:
		31-Mar-14
		Gross Amount		Accumulated Amortization			Net Amount		Weighted Average Amortization Period (years)
	Patents and trademarks	$	154,214	$	(55,712	)	$	98,502		4.9
	Software development costs for internal use		547,127		(465,543	)		81,584		1.6
	Total intangible assets	$	701,341	$	(521,255	)	$	180,086
		31-Mar-13
		Gross		Accumulated			Net		Weighted Average Amortization Period (years)
		Amount		Amortization			Amount
	Patents and trademarks	$	154,214	$	(54,251	)	$	99,963		5.9
	Software development costs for internal use		547,127		(374,827	)		172,300		2.6
	Total intangible assets	$	701,341	$	(429,078	)	$	272,263
	Amortization expense for intangible assets for the years ended March 31, 2014 and 2013 was $92,200 and $112,300, respectively.
	Future amortization of intangible assets is as follows:
	Years Ending March 31,
	2015	$	62,884
	2016		49,770
	2017		28,199
	2018		19,617
	2019		19,616
		$	180,086

Accrued_Compensation_and_Relat

Accrued Compensation and Related Expenses	12 Months Ended
	Mar. 31, 2014
Accrued Compensation and Related Expenses [Abstract]	'
Accrued Compensation and Related Expenses	'
	Note 6. Accrued Compensation and Related Expenses
	Accrued compensation and related expenses consist of the following:
		March 31,
		2014		2013
	Accrued salary and wages	$	80,328	$	85,554
	Accrued paid time off		155,166		92,376
	Accrued board of director fees		214,553		38,000
	Other accrued obligations		4,241		1,502
		$	454,288	$	217,432

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Note 7. Related Party Transactions
	Related Party Notes Payable
	As of March 31, 2014 and 2013, the Company had aggregate principal balances of $555,500 and $651,500, respectively, in outstanding unsecured indebtedness owed to four related parties, including former members of the Company's board of directors, representing working capital advances made to the Company from February 2001 through March 2005. These notes bear interest at the rate of 6% per annum and provide for aggregate monthly principal payments which began April 1, 2006 of $2,500, and which increased by an aggregate of $2,500 every nine months to a maximum of $10,000 per month. As of March 31, 2014, the aggregate principal payments totaled $8,000 per month. Any remaining unpaid principal and accrued interest is due at maturity on various dates through March 1, 2015.
	Related-party interest expense under these notes was $36,500 and $42,200 for the years ended March 31, 2014 and 2013, respectively. Accrued interest, which is included in related party notes payable in the accompanying consolidated balance sheets, amounted to $802,600 and $766,200 as of March 31, 2014 and 2013, respectively.
	Convertible Bridge Notes
	During the year ended March 31, 2014, the Company issued to certain accredited investors various unsecured promissory notes with the terms as described under Note 8. These unsecured promissory notes included $120,000 of the 5% Bridge Notes (as defined below) issued to Jerrell Shelton, the Company's Chief Executive Officer, $100,000 of the Bridge Notes (as defined below) issued to Richard Rathmann, a member of the Board of Directors of the Company, $200,000 of the Bridge Notes and $100,000 of the 5% Bridge Notes issued to GBR Investments, LLC, of which Richard Rathmann is the manager.

Convertible_Notes_Payable

Convertible Notes Payable	12 Months Ended
	Mar. 31, 2014
Convertible Notes Payable [Abstract]	'
Convertible Notes Payable	'
	Note 8. Convertible Notes Payable
	2013 and 2014 Bridge Notes
	In the fourth quarter of fiscal 2013 and first nine months of fiscal 2014, the Company issued to certain accredited investors unsecured convertible promissory notes (the "Bridge Notes") in the original principal amount of $1,294,500 and $2,765,301, respectively, for total principal of $4,059,801, pursuant to the terms of subscription agreements and letters of investment intent.
	The Bridge Notes accrued interest at a rate of 15% per annum from date of issuance until January 31, 2013 and at a rate of 5% per annum from February 1, 2013 through the date of payment, in each case on a non-compounding basis. All principal and interest under the Bridge Notes were due on December 31, 2013. Accrued interest related to these notes amounted to $0 and $9,900, as of March 31, 2014 and 2013, respectively.
	In connection with the issuance of the Bridge Notes to three accredited investors totaling $400,000 in June, July and August 2013, the Company granted these investors warrants to purchase 1,797,457 shares of common stock at an exercise prices ranging from $0.19 to $0.29 per share. The relative fair value of the warrants of $199,200 was recorded as a debt discount and was amortized to interest expense using the straight-line method which approximated the effective interest method over the term of the Bridge Notes. These Bridge Notes accrued interest at 8% per annum from the date of issuance through date of payment, on a non-compounding basis. All other terms of these Bridge Notes are consistent with the rest of the Bridge Notes. Upon conversion of the Bridge Notes in September and October 2013, the remaining unamortized debt discount was amortized to interest expense.
	In September and October 2013, the Bridge Note holders accepted an offer by the Company and converted an aggregate of $4,127,202 of outstanding principal and accrued interest under the Bridge Notes into 20,636,011 units (the "Units") at a price of $0.20 per Unit, with each Unit consisting of (i) one share of common stock of the Company ("Common Stock") and (ii) one warrant to purchase one share of Common Stock at an exercise price of $0.37 per share. The warrants are exercisable beginning on March 31, 2014 and have a term of five years from date of issuance. As the transaction was considered an induced conversion under the applicable accounting guidance, the Company recognized $13,713,767 in debt conversion expense representing the fair value of the securities transferred in excess of the fair value of the securities issuable upon the original conversion terms of the Bridge Notes. The Company calculated the fair value of the common stock issued by using the closing price of the stock on the date of issuance. The fair value of the warrants was calculated using Black-Scholes.
	Upon conversion of the Bridge Notes, the remaining unamortized debt discount was amortized to interest expense. During the years ended March 31, 2014 and 2013, the Company amortized $199,200 and $0, respectively, to interest expense.
	5% Bridge Notes
	From December 2013 to March 2014, the Company issued to certain accredited investors unsecured convertible promissory notes (the "5% Bridge Notes") in the original principal amount of $1,793,000, pursuant to the terms of subscription agreements and letters of investment intent. This includes two notes in the aggregate amount of $120,000 issued to Jerrell Shelton, the Company's Chief Executive Officer, on December 11, 2013 and January 10, 2014 as well as a note in the amount of $100,000 issued to GBR Investments, LLC on February 3, 2014, of which Richard Rathmann, a Director of the Company, is the manager.
	The 5% Bridge Notes accrue interest at a rate of 5% per annum from the date of issuance through date of payment, on a non-compounding basis. All principal and interest under the 5% Bridge Notes becomes due on June 30, 2014. Accrued interest related to these notes of $14,100 is included in convertible debentures payable and accrued interest, net of discount in the accompanying consolidated balance sheet at March 31, 2014.
	In connection with the issuance of the 5% Bridge Notes, the Company granted these investors warrants to purchase 896,500 shares of common stock at an exercise price of $0.49 per share. The warrants are exercisable on May 31, 2014 and expire on December 31, 2018. The relative fair value of the warrants of $279,100 was recorded as a debt discount and is amortized to interest expense using the straight-line method which approximates the effective interest method over the term of the 5% Bridge Notes.  During the year ended March 31, 2014, the Company amortized $94,300 of the debt discount to interest expense for these notes.
	In the event the Company designates and issues one or more types of equity securities while the 5% Bridge Notes are outstanding ("Subsequent Offering"), the Company must provide written notice to the holders of the notes and such holders will have a right to convert up to all of the principal and accrued unpaid interest on the notes into shares of such equity securities on the same terms as the Subsequent Offering during the ten days following the provision of such notice. The conversion price for these equity securities will be 90% of the offering price for the equity securities. The Company was unable to value the conversion feature of these 5% Bridge Notes given the absence of a conversion rate and the convertibility of the 5% Bridge Notes being contingent upon the completion of a Subsequent Offering. In May 2014, note holders with the principal amount of $1,743,000 converted their notes (see Note 15).
	Emergent Financial Group, Inc. ("Emergent") served as the Company's placement agent in connection with the original placement of the Bridge Notes and 5% Bridge Notes and earned a commission of 9% of the original principal balance of such notes. Debt financing costs of $375,900 and $116,500 in 2014 and 2013, respectively, comprised primarily of the commission earned by Emergent, of which $98,400 and $107,800 is recorded in other current assets in the accompanying consolidated balance sheets as of March 31, 2014 and 2013, respectively, and are being amortized to interest expense using the straight-line method which approximates the effective interest method over the term of the notes.
	In connection with the conversion of the Bridge Notes in September and October 2013, Emergent received warrants to purchase 1,911,259 shares of common stock at an exercise price of $0.20 per share. The warrants were exercisable beginning March 31, 2014 and have an expiration date of June 30, 2018. Emergent did not receive any compensation with respect to the 5% Bridge Note in the principal amount of $120,000 issued to Jerrell Shelton, the Chief Executive Officer of the Company and $100,000 issued to GBR Investments, LLC , of which Richard Rathmann, a Director of the Company, is the manager. During the years ended March 31, 2014 and 2013, the Company amortized $385,400 and $8,700, respectively, to interest expense.

Derivative_Liabilities

Derivative Liabilities	12 Months Ended
	Mar. 31, 2014
Derivative Liabilities [Abstract]	'
Derivative Liabilities	'
	Note 9. Derivative Liabilities
	In accordance with applicable accounting guidance, certain of the Company's outstanding warrants to purchase shares of common stock were treated as derivatives because these instruments had reset or ratchet provisions in the event the Company raises additional capital at a lower price, among other adjustments. As such, the fair value of these common stock purchase warrants were treated as derivative liabilities since their date of issuance or modification. Changes in fair value were recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives is higher at the subsequent balance sheet date, the Company will record a non-operating, non-cash charge. If the fair value of the derivatives is lower at the subsequent balance sheet date, the Company will record non-operating, non-cash income. As of March 31, 2014 and 2013, the Company had derivative warrant liabilities with fair values of $0 and $20,848, respectively. The derivative warrants expire in April 2014.
	During the year ended March 31, 2014 and 2013, the Company recognized aggregate gains of $20,848 and $16,486, respectively, due to the change in fair value of its derivative instruments.
	The Company's common stock purchase warrants do not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes using the following assumptions:
		March 31,
		2014	2013
	Expected life (years)	0.01 to 0.81	1.01 to 1.81
	Risk-free interest rate	0.03% - 0.15%	0.14%-0.33%
	Volatility	70% - 144%	129% - 158%
	Dividend yield	-	-
	Historical volatility was computed using daily pricing observations for recent periods that correspond to the remaining term of the warrants, which had an original term of five years from the date of issuance. The expected life is based on the remaining term of the warrants. The risk-free interest rate is based on U.S. Treasury securities with a maturity corresponding to the remaining term of the warrants.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	Note 10. Commitments and Contingencies
	Facility and Equipment Leases
	We lease 11,900 square feet of corporate, research and development, and warehouse facilities in Lake Forest, California under an operating lease expiring June 30, 2015 which includes the right to cancel the lease with a minimum of 120 day written notice at any time after December 31, 2012. We also lease corporate facilities in San Diego, California under a non-cancelable operating lease expiring December 31, 2014. Each lease agreement contains certain scheduled rent increases which are accounted for on a straight-line basis.
	Future minimum lease payments are as follows:
	Years ending March 31,	Operating Leases
	2015	$	192,800
	2016		26,700
		$	219,500
	Rent expense for the years ended March 31, 2014 and 2013 was approximately $178,000 and $204,000, respectively.
	Employment Agreements
	We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.
	Consulting and Engineering Services
	Effective November 1, 2010, the Company entered into a Second Amendment to Master Consulting and Engineering Services Agreement (the "Second Amendment") with KLATU Networks, LLC ("KLATU"), which amended the Master Consulting and Engineering Services Agreement between the parties dated as of October 9, 2007 (the "Agreement"), as amended by the First Amendment to Master Consulting and Engineering Services Agreement between the parties dated as of April 23, 2009. The parties entered into the Second Amendment to clarify their mutual intent and understanding that all license rights granted to the Company under the Agreement, as amended, shall survive any termination or expiration of the Agreement. In addition, in recognition that the Company has paid KLATU less than the market rate for comparable services, the Second Amendment provides that if the Company terminates the Agreement without cause, which the Company has no intention of doing, or liquidates, KLATU shall be entitled to receive additional consideration for its services provided from the commencement of the Agreement through such date of termination, which additional compensation shall not be less than $2 million plus two times the "cost of work" (as defined in the Agreement). Any such additional compensation would be payable in three equal installments within 12 months following the date the amount of such additional compensation is determined. If KLATU terminates that agreement, no such payments are payable.
	The agreement provides for one year terms ending on December 31 of each year, but it automatically renews for one year periods unless otherwise terminated. Consulting fees for services provided by KLATU were $395,300 and $401,100 for the years ended March 31, 2014 and 2013, respectively.
	Litigation
	The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. In the opinion of management, there are no legal matters involving the Company that would have a material adverse effect upon the Company's consolidated financial condition or results of operations.
	Indemnities and Guarantees
	The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheets.
	The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities. The duration of the guarantees and indemnities varies, and is generally tied to the life of the agreement.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	Note 11. Stockholders' Equity
	Authorized Stock
	The Company has 250,000,000 authorized shares of common stock with a par value of $0.001 per share. In September 2011, our stockholders approved an amendment to the Amended and Restated Articles of Incorporation to authorize a class of undesignated or "blank check" preferred stock, consisting of 2,500,000 shares at $0.001 par value per share. Shares of preferred stock may be issued in one or more series, with such rights, preferences, privileges and restrictions to be fixed by the Company's board of directors. In May 2014, our stockholders approved a Certificate of Designation, which designated 800,000 shares of preferred stock as Class A Preferred Stock (See Note 15).
	Common Stock Reserved for Future Issuance
	As of March 31, 2014, approximately 73.1 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options and warrants, as follows:
	Exercise of stock options	11,894,205
	Exercise of warrants	61,194,343
	Total shares of common stock reserved for future issuances	73,088,548

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Mar. 31, 2014
Stock-Based Compensation [Abstract]	'
Stock-Based Compensation	'
	Note 12. Stock-Based Compensation
	Warrant Activity
	We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Included in outstanding warrants are 262,856 and 312,856 warrants at March 31, 2014 and 2013, respectively issued to employees or directors. Our outstanding warrants expire on varying dates through July 2019. A summary of warrant activity is as follows:
			Number of			Weighted-			Weighted-		Aggregate
			Shares			Average			Average		Intrinsic
						Exercise			Remaining		Value (1)
						Price/Share			Contractual
									Term (Years)
	Outstanding - March 31, 2012			37,144,504		$	1.18
	Issued			30,000			0.5
	Exercised			-			-
	Forfeited			(123,376	)		0.77
	Expired			(23,929	)		8.89
	Outstanding - March 31, 2013			37,027,199			1.18
	Issued			25,241,227			0.35
	Exercised			(926,315	)		0.22
	Forfeited			(39,728	)		8.49
	Expired			(108,040	)		7.96
	Outstanding - March 31, 2014			61,194,343		$	0.84			2.9	$	3,987,500
	Vested (exercisable) - March 31, 2014			60,297,010		$	0.84			2.9	$	3,960,600
		-1	Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the common stock on March 31, 2014, which was $0.52 per share.
	The following table summarizes information with respect to warrants outstanding and exercisable at March 31, 2014:
	Exercise Price		Number			Weighted-			Weighted-		Number		Weighted-
			Outstanding			Average			Average		Exercisable		Average
						Remaining			Exercise Price				Exercise Price
						Contractual
						Life (Years)
	$0.19 - 0.20			2,437,574			4.3		$	0.2		2,437,574	$	0.2
	$0.21 - 0.37			20,980,838			4.5		$	0.37		20,980,838	$	0.37
	$0.38 - 0.69			10,932,429			3		$	0.67		10,035,929	$	0.69
	$0.70 - 0.92			21,431,557			1.7		$	0.77		21,431,557	$	0.77
	$0.93 - 10.80			5,411,945			0.9		$	3.53		5,411,112	$	3.53
				61,194,343								60,297,010
	Stock Options
	We have three stock incentive plans: the 2002 Stock Incentive Plan, or the 2002 Plan, the 2009 Stock Incentive Plan, or the 2009 Plan and the 2011 Stock Incentive Plan, or the 2011 Plan (collectively, the "Plans"). The 2002 Plan authorizes the grant of incentive awards, including stock options, for the purchase of up to a total of 500,000 shares and has no shares available for future issuances as the 2002 Plan has expired. Subsequent to the adoption of the 2011 Plan, no new options have been granted pursuant the 2009 Plan or 2002 Plan. In September 2009, the stockholders approved the issuance of up to 1,200,000 shares of common stock available for issuance under the 2009 Plan and as of March 31, 2014, the Company has 299,741 shares available for future awards under the 2009 Plan. In September 2011, the stockholders authorized the issuance of up to 2,300,000 shares of the Company's common stock. On September 13, 2012, the stockholders approved an increase to the number of shares of the Company's common stock available for issuance by 3,000,000 shares. On September 6, 2013 the stockholders approved an increase to the number of shares of the Company's common stock available for issuance by 7,100,000 shares. As of March 31, 2014, there were 7,405,004 incentive awards available for grant under the 2011 Plan.
	During each of the two years in the period ended March 31, 2014, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:
			March 31,
			2014			2013
	Expected life (years)			1.6 - 6.02			2.6 -10.0
	Risk-free interest rate			0.19% - 1.84%			0.63%-2.22%
	Volatility			127% - 140%			124% - 166%
	Dividend yield			0	%		0	%
	The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the historical volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.
	We recognize stock-based compensation cost over the vesting period using the straight-line single option method. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. An estimated forfeiture rate has been applied to unvested awards for the purpose of calculating compensation cost. The estimated forfeiture rate of 0% per year is based on the historical forfeiture activity of unvested stock options. These estimates are revised, if necessary, in future periods if actual forfeitures differ from the estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
	A summary of stock option activity is as follows:
			Number of			Weighted-			Weighted-		Aggregate
			Shares			Average			Average		Intrinsic
						Exercise			Remaining		Value (1)
						Price/Share			Contractual
									Term (Years)
	Outstanding - March 31, 2012			1,355,132		$	1.14
	Granted (weighted-average fair value of $0.26 per share)			4,063,109			0.29
	Exercised			-			-
	Forfeited			(322,500	)		0.98
	Expired			-			-
	Outstanding - March 31, 2013			5,095,741		$	0.47
	Granted (weighted-average fair value of $0.24 per share)			7,673,272			0.28
	Exercised			(657,000	)		0.2
	Forfeited			(197,808	)		0.32
	Expired			(20,000	)		6
	Outstanding - March 31, 2014			11,894,205		$	0.35			8.6	$	2,578,900
	Vested (exercisable) - March 31, 2014			5,543,002		$	0.42			8	$	1,110,600
	Unvested (unexercisable) - March 31, 2014			6,351,203		$	0.3			3	$	1,468,300
	-1	Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on March 31, 2014, which was $0.52 per share.
The following table summarizes information with respect to stock options outstanding and exercisable at March 31, 2014:
Exercise Price		Number			Weighted-			Weighted-		Number		Weighted-
		Outstanding			Average			Average		Exercisable		Average
					Remaining			Exercise				Exercise
					Contractual			Price				Price
					Life (Years)
$0.17 - 0.48			10,523,036			8.9		$	0.27		4,428,083	$	0.27
$0.52 - 0.98			1,234,469			6.3		$	0.66		987,594	$	0.66
$1.05 - 2.20			48,600			6.4		$	1.64		39,225	$	1.69
$4.30 - 8.31			88,100			2.3		$	4.74		88,100	$	4.74
			11,894,205								5,543,002
As of March 31, 2014, there was unrecognized compensation expense of $1.6 million related to unvested stock options, which we expect to recognize over a weighted average period of 3.0 years.

Income_Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	Note 13. Income Taxes
	Significant components of the Company's deferred tax assets as of March 31, 2014 and 2013 are shown below:
		March 31,
		2014			2013
	Deferred tax assets:	(000's)
	Net operating loss carryforward	$	15,379		$	13,505
	Research credits		60			51
	Expenses recognized for granting of options and warrants		1,651			1,319
	Accrued expenses and reserves		135			32
	Valuation allowance		(17,225	)		(14,907	)
		$	-		$	-
	Based on the weight of available evidence, the Company's management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company's income tax provision consists of state minimum taxes.
	The income tax provision differs from that computed using the federal statutory rate applied to income before taxes as follows:
		March 31,
		2014			2013
	Computed tax benefit at federal statutory rate	$	(6,650,000	)	$	(2,169,000	)
	State tax, net of federal benefit		(327,000	)		(359,000	)
	Warrant MTM Adjustment		(7,000	)		(6,000	)
	Induced conversion costs		4,663,000			-
	Interest expense		-			1,000
	Permanent items and other		4,600			215,600
	Valuation allowance		2,318,000			2,319,000
		$	1,600		$	1,600
	At March 31, 2014, the Company has federal and state net operating loss carryforwards of approximately $39,086,000 and $35,759,000 which will begin to expire in 2020, unless previously utilized, and as of 2012 have already begun to for state carryforwards. At March 31, 2014, the Company has federal and California research and development tax credits of approximately $18,000 and $64,000, respectively. The federal research tax credit begins to expire in 2026 unless previously utilized and the California research tax credit has no expiration date.
	Utilization of the net operating loss and research and development carryforwards might be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an "ownership change" as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company's formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders' subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition.
	The Company has not completed a study to assess whether an ownership change has occurred. If the Company has experienced an ownership change, utilization of the NOL or R&D credit carryforwards would be subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company's stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance.
	On September 13, 2013, the U.S. Treasury Department released final income tax regulations on the deduction and capitalization of expenditures related to tangible property. These final regulations apply to tax years beginning on or after January 1, 2014, and may be adopted in earlier years. The Company does not intend to early adopt the tax treatment of expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property as of January 1, 2013. The tangible property regulations will require the Company to make additional tax accounting method changes as of January 1, 2014; however, management does not anticipate the impact of these changes to be material to the Company's consolidated financial position, its results of operations and its footnote disclosures.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Mar. 31, 2014
Quarterly Financial Data (Unaudited) [Abstract]	'
Quarterly Financial Data (Unaudited)	'
	Note 14. Quarterly Financial Data (Unaudited)
	A summary of quarterly financial data is as follows ($ in '000's):
		Quarter Ended
		30-Jun			September 30			31-Dec			31-Mar
	Year ended March 31, 2014
	Total revenues	$	488		$	580		$	757		$	835
	Gross margin	$	55		$	72		$	167		$	143
	Operating loss	$	(1,260	)	$	(1,287	)	$	(1,257	)	$	(1,274	)
	Net loss	$	(1,324	)	$	(14,960	)	$	(1,840	)	$	(1,441	)
	Net loss per share, basic and diluted	$	(0.03	)	$	(0.38	)	$	(0.03	)	$	(0.02	)
	Year ended March 31, 2013
	Total revenues	$	191		$	234		$	307		$	368
	Gross loss	$	(163	)	$	(111	)	$	(62	)	$	(153	)
	Operating loss	$	(1,541	)	$	(1,554	)	$	(1,549	)	$	(1,681	)
	Net loss	$	(1,546	)	$	(1,551	)	$	(1,567	)	$	(1,717	)
	Net loss per share, basic and diluted	$	(0.04	)	$	(0.04	)	$	(0.04	)	$	(0.05	)
	Earnings per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the year.

Subsequent_Events

Subsequent Events	12 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 15. Subsequent Events
	Designation of Class A Preferred Stock
	On May 2, 2014, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation which designated 800,000 shares of the Company's previously authorized preferred stock, par value $0.001, as Class A Preferred Stock ("Preferred Stock").
		The	rights, preferences, and privileges of the Preferred Stock are summarized as follows:
		·	Dividends shall accrue on shares of Preferred Stock at the rate of $0.96 per annum. Such dividends shall accrue day-to-day, shall be cumulative, and shall be payable on when, as, and if declared by the Board of Directors of the Company.
		·	In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Registrant, holders of Preferred Stock then outstanding shall be entitled to receive a preference payment equal to $12.00 per share (subject to appropriate adjustment in the event of a stock dividend, split, combination, or other similar recapitalization) plus any accrued dividends, but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon.
		·	Shares of Preferred Stock shall vote together with the common stock on an as-converted basis.
		·	At any time after September 1, 2014, shares of Preferred Stock shall be convertible into thirty shares of Common Stock. In addition, accrued but unpaid dividends on the Preferred Stock will also be convertible into common stock after September 1, 2014 at the rate of one share for each $0.40 of dividend. Such conversion is subject to adjustment in the event of any stock split or combination, certain dividends and distributions, and any reorganization, recapitalization, reclassification, consolidation, or merger involving the Company.
		·	Shares of the Preferred Stock shall be subject to redemption by the Company at any time on or after January 15, 2017, upon payment of $12.00 per share (subject to appropriate adjustment in the event of a stock dividend, split, combination, or other similar recapitalization) plus all accrued but unpaid dividends thereon.
		·	The Preferred Stock is subject to a liquidation preference over common stock equal to $12 per share and the unpaid accrued dividend.  Holders of the Preferred Stock will vote with holders of the Company's common stock, but will have thirty votes per share of Preferred Stock held compared to one vote for each share of common stock.
	Issuance of Class A Preferred Stock
	In May 2014, the Company entered into definitive agreements for a private placement of its securities to certain institutional and accredited investors (the "Investors") pursuant to certain Subscription Agreements and Elections to Convert between the Company and the Investors. Through June 13, 2014, aggregate gross cash proceeds of $839,600 (approximately $628,700 after estimated cash offering expenses) were collected in exchange for the issuance of 69,964 shares of our Class A Preferred Stock, and warrants, exercisable for five years, to purchase up to a total of 559,712 shares of our common stock at an exercise price of $0.50 per share. The Company intends to use the net proceeds for working capital purposes.
	Pursuant to the Subscription Agreements, the Company issued shares of a newly established Class A Preferred Stock and warrants to purchase common stock of Cryoport. The shares and warrants were issued as a unit (a "Unit") consisting of (i) one share of Class A Convertible Preferred Stock and (ii) one warrant to purchase eight (8) shares of Common Stock at an exercise price of $0.50 per share, which are immediately exercisable and may be exercised at any time on or before March 31, 2019.
	Pursuant to the terms of the 5% Bridge Notes issued by the Company between December 6, 2013 and March 13, 2014 with a total original principal amount of $1,793,000 (the "5% Bridge Notes"), the issuance of the Units to Investors at $12.00 per Unit entitled the holders of the 5% Bridge Notes to convert up to the entire principal amount and accrued interest under the 5% Bridge Notes into Units at a rate of $10.80 per Unit. Through June 13, 2014, 5% Bridge Note holders totaling $1,743,000 in original principal sum elected to convert their 5% Bridge Notes, including accrued interest, for Units in exchange for the issuance of 163,608 shares of our Class A Preferred Stock and warrants to purchase up to 1,308,864 shares of our commons stock at an exercise price of $0.50 per share. Two of the 5% Bridge Note holders that executed Subscription Agreements to convert 5% Bridge Notes in the aggregate principal amount of $220,000, are affiliates of the Company - Jerrell W. Shelton, the Company's Chief Executive Officer, and GBR Investments, LLC, which is managed by Richard Rathmann, a Director and Chairman of the Board of Directors of the Company (collectively, the "Affiliates").
	Emergent Financial Group, Inc. served as the Company's placement agent in this transaction and received, with respect to the gross proceeds received from Investors who converted their 5% Bridge Notes into Units (not including those conversions by the Affiliates), a commission of 3% and a non-accountable finance fee of 1% of such proceeds, and with respect to gross proceeds received from all other Investors, a commission of 10% and a non-accountable finance fee of 3% of the aggregate gross proceeds received from such Investors, plus reimbursement of legal expenses of up to $40,000. Emergent Financial Group, Inc. will also be issued a warrant to purchase three shares of Common Stock at an exercise price of $0.50 per share for each Unit issued in this transaction. The Company and Emergent Financial Group, Inc. have agreed that the offering of Units to new Investors will conclude on July 14, 2014.
	As of June 13, 2014, 233,572 shares of Preferred Stock and 1,868,576 of the related warrants were outstanding for Investors and 638,646 warrants were outstanding for Emergent in connection with the Preferred Stock offering and the 5% Bridge Notes conversion.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiary, Cryoport Systems, Inc. All intercompany accounts and transactions have been eliminated.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company's significant estimates include allowances for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, valuation of derivative liabilities and valuation of common stock, warrants and stock options issued for products or services.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company's financial instruments consist of cash and cash equivalents, accounts receivable, related-party notes payable, convertible notes payable, accounts payable and accrued expenses. The carrying value for all such instruments approximates fair value at March 31, 2014 and 2013 due to their short-term nature. The difference between the fair value and recorded values of the related party notes payable is not significant.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers highly liquid investments with original maturities of 90 days or less to be cash equivalents.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	The Company maintains its cash accounts in financial institutions. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") with basic deposit insurance coverage limits up to $250,000 per owner. At March 31, 2014 and 2013, the Company had cash balances of approximately $159,000 and $214,000, respectively, which exceeded the FDIC insurance limit. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.
Customers	'
	Customers
	The Company grants credit to customers within the U.S. and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for a limited number of established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company's ability to collect receivables is affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at March 31, 2014 and 2013 are net of reserves for doubtful accounts of $24,600 and $8,700, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts.
	The majority of the Company's customers are in the biotechnology, pharmaceutical and life science industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. At March 31, 2014, there was one customer that accounted for 30.6% of net accounts receivable. No other single customer owed us more than 10% of net accounts receivable at March 31, 2014 and 2013. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded our estimates.
	The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During fiscal years 2014 and 2013, the Company had revenues from foreign customers of approximately $434,000 and $161,000, respectively, which constituted approximately 16.3% and 14.6% of total revenues, respectively. For the fiscal year ended March 31, 2014, there was one customer that accounted for 30.8% of net revenues. No other single customer generated over 10% of net revenues during 2014 and 2013.
Inventories	'
	Inventories
	The Company's inventories consist of accessories that are sold and shipped to customers along with pay-per-use containers that are not returned to the Company with the containers at the culmination of the customer's shipping cycle. Inventories are stated at the lower of cost or current estimated market value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, and based on the evaluation, records adjustments to reflect inventories at its net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company's products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company's forecasts of market conditions, industry trends, competition and other factors.
Property and Equipment	'
	Property and Equipment
	The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company's arrangements are similar to the accounting standard for leases since they convey the right to use the container over a period of time. The Company retains the title to the containers and provides its customers the use of the container for a specific shipping cycle. At the culmination of the customer's shipping cycle, the container is returned to the Company. As a result, the Company classifies the containers as fixed assets for the per-use container program.
	Property and equipment are recorded at cost. Cryogenic shippers, which comprise of 89% and 87% of the Company's net property and equipment balance at March 31, 2014 and 2013, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Equipment acquired under capital leases is amortized over the estimated useful life of the assets or term of the lease, whichever is shorter and included in depreciation expense.
	Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in current operations.
Intangible Assets	'
	Intangible Assets
	Intangible assets are comprised of patents and trademarks and software development costs. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years. The Company capitalizes certain costs related to software developed for internal use. Software development costs incurred during the preliminary or maintenance project stages are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized using the straight-line method over the estimated useful life of the software, which is five years. Capitalized costs include purchased materials and costs of services including the valuation of warrants issued to consultants.
Long-lived Assets	'
	Long-lived Assets
	If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets' carrying value, and accordingly, we have not recognized any impairment losses through March 31, 2014.
Deferred Financing Costs	'
	Deferred Financing Costs
	Deferred financing costs represent costs incurred in connection with the issuance of the convertible notes payable and private equity financing. Deferred financing costs related to the issuance of debt are being amortized over the term of the financing instrument using the effective interest method while deferred financing costs from equity financings are netted against the gross proceeds received from the equity financings.
	In connection with the 5% Bridge Notes, during the third and fourth quarter of fiscal 2014, the Company incurred financing costs that have been capitalized and are being amortized over the term of the convertible bridge notes payable using the straight-line method which approximates the effective interest method (see Note 8).
	During the year ended March 31, 2013, the Company incurred $103,542 of offering costs in connection with the private placement that closed in February and March 2012, which were charged to additional paid-in capital and netted against the proceeds received in the private placements. As of March 31, 2013, offering costs of $53,747 related to the private placement were included in accounts payable and accrued expenses in the accompanying consolidated balance sheet.
Convertible Debentures	'
	Convertible Debentures
	If a conversion feature of conventional convertible debt is not accounted for as a derivative instrument and provides for a rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature ("BCF"). A BCF is recorded by the Company as a debt discount. The convertible debt is recorded net of the discount related to the BCF. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method.
Derivative Liabilities	'
	Derivative Liabilities
	Certain of the Company's issued and outstanding common stock purchase warrants which have exercise price reset features are treated as derivatives for accounting purposes. The common stock purchase warrants were not issued with the intent of effectively hedging any future cash flow, fair value of any asset, liability or any net investment in a foreign operation. The warrants do not qualify for hedge accounting, and as such, all future changes in the fair value of these warrants are recognized currently in earnings until such time as the warrants are exercised, expire or the related rights have been waived. These common stock purchase warrants do not trade in an active securities market, and as such, the Company estimates the fair value of these warrants using the Black-Scholes option pricing model ("Black-Scholes") (see Note 9).
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under the provision of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 740, Income Taxes , or ASC 740. As of March 31, 2014 and 2013, there were no unrecognized tax benefits included in the accompanying consolidated balance sheets that would, if recognized, affect the effective tax rates.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company's management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company's income tax provision consists of state minimum taxes.
	The Company's policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets at March 31, 2014 and 2013, respectively and has not recognized interest and/or penalties in the consolidated statement of operations for the years ended March 31, 2014 and 2013. The Company is subject to taxation in the U.S. and various state jurisdictions. As of March 31, 2014, the Company is no longer subject to U.S. federal examinations for years before 2010 and for California franchise and income tax examinations for years before 2009. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by U.S. federal or state jurisdictions.
Revenue Recognition	'
	Revenue Recognition
	The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company's arrangements are similar to the accounting standard for leases since they convey the right to use the containers over a period of time. The Company retains title to the containers and provides its customers the use of the container for a specified shipping cycle. At the culmination of the customer's shipping cycle, the container is returned to the Company.
	The Company recognizes revenue for the use of the shipper at the time of the delivery of the shipper to the end user of the enclosed materials, and at the time that collectability is reasonably certain. Revenue is based on gross net of discounts and allowances.
	The Company also provides logistics support and management to some customers, which may include onsite logistics personnel. Revenue is recognized for these services as services are rendered and at the time that collectability is reasonably certain.
Accounting for Shipping and Handling Revenue, Fees and Costs	'
	Accounting for Shipping and Handling Revenue, Fees and Costs
	The Company classifies amounts billed for shipping and handling as revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying consolidated statements of operations.
Research and Development Expenses	'
	Research and Development Expenses
	Expenditures relating to research and development are expensed in the period incurred.
Stock-based Compensation	'
	Stock-based Compensation
	The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at grant date using Black-Scholes and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period.
	Since stock-based compensation is recognized only for those awards that are ultimately expected to vest, the Company has applied an estimated forfeiture rate to unvested awards for the purpose of calculating compensation cost. These estimates will be revised, if necessary, in future periods if actual forfeitures differ from estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs. The estimated forfeiture rates at March 31, 2014 and 2013 was zero as the Company has not had a significant history of forfeitures and does not expect significant forfeitures in the future.
	Cash flows from the tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options or warrants are classified as financing cash flows. Due to the Company's loss position, there were no such tax benefits during years ended March 31, 2014 and 2013.
	The Company uses Black-Scholes to estimate the fair value of stock-based awards. The determination of fair value using Black-Scholes is affected by the Company's stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.
	The Company's stock-based compensation plans are discussed further in Note 12.
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services	'
	Equity Instruments Issued to Non-Employees for Acquiring Goods or Services
	Issuances of the Company's common stock for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a "performance commitment" which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.
Basic and Diluted Net Income (Loss) Per Share	'
	Basic and Diluted Net Income (Loss) Per Share
	We calculate basic and diluted net income (loss) per share using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for preferred stock dividends (if any) declared during the period. In periods of a net loss position, basic and diluted weighted average shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and other common stock equivalents outstanding during the periods.
	The following shows the amounts used in computing net loss per share for each of the two years in the period ended March 31, 2014:
		Years Ended March 31,
		2014			2013
	Net loss	$	(19,565,426	)	$	(6,382,433	)
	Less:
	Preferred dividends paid in cash or stock		-			-
	Loss attributable to Cryoport stockholders	$	(19,565,426	)	$	(6,382,433	)
	Weighted average shares issued and outstanding		48,850,513			37,760,628
	Basic and diluted net loss per share	$	(0.40	)	$	(0.17	)
	The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would have been anti-dilutive:
		Years Ended March 31,
		2014			2013
	Stock options		3,458,313			411,762
	Warrants		3,221,728			-
			6,680,041			411,762
Segment Reporting	'
	Segment Reporting
	We currently operate in one reportable segment.
Fair Value Measurements	'
	Fair Value Measurements
	We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
	Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Currently we do not have any items classified as Level 2.
	Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.
	We did not elect the fair value option, as allowed, to account for financial assets and liabilities that were not previously carried at fair value. Therefore, material financial assets and liabilities that are not carried at fair value, such as trade accounts receivable and payable, are reported at their historical carrying values.
	The carrying values of our assets and liabilities that are required to be measured at fair value on a recurring basis as of March 31, 2014 and 2013 are classified in the table below in one of the three categories of the fair value hierarchy described below:
		Fair Value Measurements
		Level 1			Level 2			Level 3		Total
	31-Mar-13
	Liabilities:
	Derivative liabilities	$	-		$	-		$	20,848	$	20,848
	The following summarizes the activity of Level 3 inputs measured on a recurring basis for the years ended March 31, 2014 and 2013:
		Fair Value Measurements of  Unobservable Inputs (Level 3)
	Balance at March 31, 2012	$	37,334
	Transfers in / (out) of Level 3		-
	Adjustments resulting from a change in fair value of derivative liabilities		(16,486	)
	Balance at March 31, 2013		20,848
	Transfers in / (out) of Level 3		-
	Adjustments resulting from a change in fair value of derivative liabilities		(20,848	)
	Balance at March 31, 2014	$	-
	The fair value of derivative liabilities were measured on their respective origination dates and at the end of each reporting period using Level 3 inputs. The significant assumptions we use in the calculations under Black-Scholes as of March 31, 2014 and 2013 included an expected term based on the remaining contractual life of the warrants, a risk-free interest rate based upon observed interest rates appropriate for the expected term of the instruments, volatility based on the historical volatility of our common stock, and a zero dividend rate based on our past, current and expected practices of granting dividends on common stock.
Foreign Currency Translation	'
	Foreign Currency Translation
	We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any of the periods presented.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, the FASB issued ASU No. 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists." ASU 2013-11 provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. This pronouncement is effective for reporting periods beginning on or after January 1, 2013. The adoption of ASU 2011-11 did not have a material impact on the Company's consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers". ASU 2014-09 supersedes the revenue recognition requirements in FASB Topic 605, "Revenue Recognition". The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, and early adoption is prohibited. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Management is currently assessing the impact the adoption of ASU 2014-09 will have on our consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2014
Summary of Significant Accounting Policies [Abstract]	'
Schedule of Earnings Per Share	'
	The following shows the amounts used in computing net loss per share for each of the two years in the period ended March 31, 2014:
		Years Ended March 31,
		2014			2013
	Net loss	$	(19,565,426	)	$	(6,382,433	)
	Less:
	Preferred dividends paid in cash or stock		-			-
	Loss attributable to Cryoport stockholders	$	(19,565,426	)	$	(6,382,433	)
	Weighted average shares issued and outstanding		48,850,513			37,760,628
	Basic and diluted net loss per share	$	(0.40	)	$	(0.17	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would have been anti-dilutive:
		Years Ended March 31,
		2014			2013
	Stock options		3,458,313			411,762
	Warrants		3,221,728			-
			6,680,041			411,762
Schedule of Liabilities Measured at Fair Value on Recurring Basis	'
	The carrying values of our assets and liabilities that are required to be measured at fair value on a recurring basis as of March 31, 2014 and 2013 are classified in the table below in one of the three categories of the fair value hierarchy described below:
		Fair Value Measurements
		Level 1			Level 2			Level 3		Total
	31-Mar-13
	Liabilities:
	Derivative liabilities	$	-		$	-		$	20,848	$	20,848
Schedule of Level 3 Inputs Measured on Recurring Basis	'
	The following summarizes the activity of Level 3 inputs measured on a recurring basis for the years ended March 31, 2014 and 2013:
		Fair Value Measurements of  Unobservable Inputs (Level 3)
	Balance at March 31, 2012	$	37,334
	Transfers in / (out) of Level 3		-
	Adjustments resulting from a change in fair value of derivative liabilities		(16,486	)
	Balance at March 31, 2013		20,848
	Transfers in / (out) of Level 3		-
	Adjustments resulting from a change in fair value of derivative liabilities		(20,848	)
	Balance at March 31, 2014	$	-

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Schedule of Inventories	'
	Inventories consist of the following:
		March 31,
		2014		2013
	Raw materials	$	18,283	$	28,533
	Finished goods		11,420		10,679
		$	29,703	$	39,212

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Mar. 31, 2014
Property and Equipment [Abstract]	'
Schedule of Property and Equipment	'
	Property and equipment consist of the following:
		March  31,
		2014			2013
	Cryogenic shippers	$	1,037,286		$	962,565
	Furniture and fixtures		30,746			30,746
	Machinery and equipment		386,731			380,526
	Leasehold improvements		30,913			30,913
			1,485,676			1,404,750
	Less accumulated depreciation and amortization		(1,076,784	)		(899,265	)
		$	408,892		$	505,485

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2014
Intangible Assets [Abstract]	'
Schedule of Intangible Assets	'
	Intangible assets consist of the following:
		31-Mar-14
		Gross Amount		Accumulated Amortization			Net Amount		Weighted Average Amortization Period (years)
	Patents and trademarks	$	154,214	$	(55,712	)	$	98,502		4.9
	Software development costs for internal use		547,127		(465,543	)		81,584		1.6
	Total intangible assets	$	701,341	$	(521,255	)	$	180,086
		31-Mar-13
		Gross		Accumulated			Net		Weighted Average Amortization Period (years)
		Amount		Amortization			Amount
	Patents and trademarks	$	154,214	$	(54,251	)	$	99,963		5.9
	Software development costs for internal use		547,127		(374,827	)		172,300		2.6
	Total intangible assets	$	701,341	$	(429,078	)	$	272,263
Schedule of Future Amortization of Intangible Assets	'
	Future amortization of intangible assets is as follows:
	Years Ending March 31,
	2015	$	62,884
	2016		49,770
	2017		28,199
	2018		19,617
	2019		19,616
		$	180,086

Accrued_Compensation_and_Relat1

Accrued Compensation and Related Expenses (Tables)	12 Months Ended
	Mar. 31, 2014
Accrued Compensation and Related Expenses [Abstract]	'
Schedule of Accrued Compensation and Related Expenses	'
	Accrued compensation and related expenses consist of the following:
		March 31,
		2014		2013
	Accrued salary and wages	$	80,328	$	85,554
	Accrued paid time off		155,166		92,376
	Accrued board of director fees		214,553		38,000
	Other accrued obligations		4,241		1,502
		$	454,288	$	217,432

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	12 Months Ended
	Mar. 31, 2014
Derivative Liabilities [Abstract]	'
Schedule of Fair Value Assumptions for Derivative Liabilities	'
	The Company's common stock purchase warrants do not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes using the following assumptions:
		March 31,
		2014	2013
	Expected life (years)	0.01 to 0.81	1.01 to 1.81
	Risk-free interest rate	0.03% - 0.15%	0.14%-0.33%
	Volatility	70% - 144%	129% - 158%
	Dividend yield	-	-

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
Schedule of Future Minimum Lease Payments	'
	Future minimum lease payments are as follows:
	Years ending March 31,	Operating Leases
	2015	$	192,800
	2016		26,700
		$	219,500

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Schedule of Common Stock Reserved for Future Issuance	'
	As of March 31, 2014, approximately 73.1 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options and warrants, as follows:
	Exercise of stock options	11,894,205
	Exercise of warrants	61,194,343
	Total shares of common stock reserved for future issuances	73,088,548

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Warrant Activity	'
	Our outstanding warrants expire on varying dates through July 2019. A summary of warrant activity is as follows:
			Number of			Weighted-			Weighted-		Aggregate
			Shares			Average			Average		Intrinsic
						Exercise			Remaining		Value (1)
						Price/Share			Contractual
									Term (Years)
	Outstanding - March 31, 2012			37,144,504		$	1.18
	Issued			30,000			0.5
	Exercised			-			-
	Forfeited			(123,376	)		0.77
	Expired			(23,929	)		8.89
	Outstanding - March 31, 2013			37,027,199			1.18
	Issued			25,241,227			0.35
	Exercised			(926,315	)		0.22
	Forfeited			(39,728	)		8.49
	Expired			(108,040	)		7.96
	Outstanding - March 31, 2014			61,194,343		$	0.84			2.9	$	3,987,500
	Vested (exercisable) - March 31, 2014			60,297,010		$	0.84			2.9	$	3,960,600
		-1	Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the common stock on March 31, 2014, which was $0.52 per share.
Schedule of Fair Value Assumptions of Stock Options	'
	The fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:
			March 31,
			2014			2013
	Expected life (years)			1.6 - 6.02			2.6 -10.0
	Risk-free interest rate			0.19% - 1.84%			0.63%-2.22%
	Volatility			127% - 140%			124% - 166%
	Dividend yield			0	%		0	%
Schedule of Stock Option Activity	'
	A summary of stock option activity is as follows:
			Number of			Weighted-			Weighted-		Aggregate
			Shares			Average			Average		Intrinsic
						Exercise			Remaining		Value (1)
						Price/Share			Contractual
									Term (Years)
	Outstanding - March 31, 2012			1,355,132		$	1.14
	Granted (weighted-average fair value of $0.26 per share)			4,063,109			0.29
	Exercised			-			-
	Forfeited			(322,500	)		0.98
	Expired			-			-
	Outstanding - March 31, 2013			5,095,741		$	0.47
	Granted (weighted-average fair value of $0.24 per share)			7,673,272			0.28
	Exercised			(657,000	)		0.2
	Forfeited			(197,808	)		0.32
	Expired			(20,000	)		6
	Outstanding - March 31, 2014			11,894,205		$	0.35			8.6	$	2,578,900
	Vested (exercisable) - March 31, 2014			5,543,002		$	0.42			8	$	1,110,600
	Unvested (unexercisable) - March 31, 2014			6,351,203		$	0.3			3	$	1,468,300
		-1	Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on March 31, 2014, which was $0.52 per share.
Warrants [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Information by Exercise Price Range	'
	The following table summarizes information with respect to warrants outstanding and exercisable at March 31, 2014:
	Exercise Price		Number			Weighted-			Weighted-		Number		Weighted-
			Outstanding			Average			Average		Exercisable		Average
						Remaining			Exercise Price				Exercise Price
						Contractual
						Life (Years)
	$0.19 - 0.20			2,437,574			4.3		$	0.2		2,437,574	$	0.2
	$0.21 - 0.37			20,980,838			4.5		$	0.37		20,980,838	$	0.37
	$0.38 - 0.69			10,932,429			3		$	0.67		10,035,929	$	0.69
	$0.70 - 0.92			21,431,557			1.7		$	0.77		21,431,557	$	0.77
	$0.93 - 10.80			5,411,945			0.9		$	3.53		5,411,112	$	3.53
				61,194,343								60,297,010
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Information by Exercise Price Range	'
	The following table summarizes information with respect to stock options outstanding and exercisable at March 31, 2014:
	Exercise Price		Number			Weighted-			Weighted-		Number		Weighted-
			Outstanding			Average			Average		Exercisable		Average
						Remaining			Exercise				Exercise
						Contractual			Price				Price
						Life (Years)
	$0.17 - 0.48			10,523,036			8.9		$	0.27		4,428,083	$	0.27
	$0.52 - 0.98			1,234,469			6.3		$	0.66		987,594	$	0.66
	$1.05 - 2.20			48,600			6.4		$	1.64		39,225	$	1.69
	$4.30 - 8.31			88,100			2.3		$	4.74		88,100	$	4.74
				11,894,205								5,543,002

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Schedule of Deferred Tax Assets	'
	Significant components of the Company's deferred tax assets as of March 31, 2014 and 2013 are shown below:
		March 31,
		2014			2013
	Deferred tax assets:	(000's)
	Net operating loss carryforward	$	15,379		$	13,505
	Research credits		60			51
	Expenses recognized for granting of options and warrants		1,651			1,319
	Accrued expenses and reserves		135			32
	Valuation allowance		(17,225	)		(14,907	)
		$	-		$	-
Schedule of Income Tax Provision	'
	The income tax provision differs from that computed using the federal statutory rate applied to income before taxes as follows:
		March 31,
		2014			2013
	Computed tax benefit at federal statutory rate	$	(6,650,000	)	$	(2,169,000	)
	State tax, net of federal benefit		(327,000	)		(359,000	)
	Warrant MTM Adjustment		(7,000	)		(6,000	)
	Induced conversion costs		4,663,000			-
	Interest expense		-			1,000
	Permanent items and other		4,600			215,600
	Valuation allowance		2,318,000			2,319,000
		$	1,600		$	1,600

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Mar. 31, 2014
Quarterly Financial Data (Unaudited) [Abstract]	'
Schedule of Quarterly Financial Data	'
	A summary of quarterly financial data is as follows ($ in '000's):
		Quarter Ended
		30-Jun			September 30			31-Dec			31-Mar
	Year ended March 31, 2014
	Total revenues	$	488		$	580		$	757		$	835
	Gross margin	$	55		$	72		$	167		$	143
	Operating loss	$	(1,260	)	$	(1,287	)	$	(1,257	)	$	(1,274	)
	Net loss	$	(1,324	)	$	(14,960	)	$	(1,840	)	$	(1,441	)
	Net loss per share, basic and diluted	$	(0.03	)	$	(0.38	)	$	(0.03	)	$	(0.02	)
	Year ended March 31, 2013
	Total revenues	$	191		$	234		$	307		$	368
	Gross loss	$	(163	)	$	(111	)	$	(62	)	$	(153	)
	Operating loss	$	(1,541	)	$	(1,554	)	$	(1,549	)	$	(1,681	)
	Net loss	$	(1,546	)	$	(1,551	)	$	(1,567	)	$	(1,717	)
	Net loss per share, basic and diluted	$	(0.04	)	$	(0.04	)	$	(0.04	)	$	(0.05	)

Nature_of_the_Business_Details

Nature of the Business (Details) (USD $)	0 Months Ended	12 Months Ended
	Mar. 15, 2005	Mar. 31, 2014	Mar. 31, 2013	Feb. 28, 2014
Nature of the Business [Abstract]	'	'	'	'
Shares issued for acquisition	2,410,811	'	'	'
Shares to be received	'	'	'	150,000
Accumulated deficit	'	($85,876,874)	($66,311,448)	'
Net loss	'	-19,563,826	-6,380,833	'
Debt conversion expense	'	$13,713,767	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Significant Accounting Policies Additional Information [Line Items]	'	'
Basic deposit coverage limit of accounts insured	$250,000	'
Cash balances, exceeded the FDIC insurance limits	159,000	214,000
Allowance for doubtful accounts receivable	24,600	8,700
Offering costs in connection with private placement	'	103,542
Offering costs in connection with equity financing included in accounts payable	'	53,747
Patents and Trademark [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Intangible assets, estimated useful life	'5 years	'
Software [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Intangible assets, estimated useful life	'5 years	'
Cryogenic Shippers [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Cryogenic shippers percentage of total property plant and equipment	89.00%	87.00%
Estimated useful lives, property and equipment	'3 years	'
Equipment and Furniture [Member] | Minimum [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Estimated useful lives, property and equipment	'3 years	'
Equipment and Furniture [Member] | Maximum [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Estimated useful lives, property and equipment	'7 years	'
Foreign Customers [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Revenues	$434,000	$161,000
Net receivables [Member] | Customer One [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Concentration risk, percentage	30.60%	'
Revenues [Member] | Customer One [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Concentration risk, percentage	30.80%	'
Revenues [Member] | Foreign Customers [Member]	'	'
Significant Accounting Policies Additional Information [Line Items]	'	'
Concentration risk, percentage	16.30%	14.60%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Schedule of Earnings Per Share) (Details) (USD $)	3 Months Ended								12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'	'	'	'	'	'	'	'	'	'
Net loss	($1,441,000)	($1,840,000)	($14,960,000)	($1,324,000)	($1,717,000)	($1,567,000)	($1,551,000)	($1,546,000)	($19,565,426)	($6,382,433)
Preferred dividends paid in cash or stock	'	'	'	'	'	'	'	'	'	'
Loss attributable to Cryoport stockholders	'	'	'	'	'	'	'	'	($19,565,426)	($6,382,433)
Weighted average shares issued and outstanding	'	'	'	'	'	'	'	'	48,850,513	37,760,628
Basic and diluted net loss per share	($0.02)	($0.03)	($0.38)	($0.03)	($0.05)	($0.04)	($0.04)	($0.04)	($0.40)	($0.17)

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Schedule of Antidilutive Shares) (Details)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares not included in computation of earnings per share	6,680,041	411,762
Stock options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares not included in computation of earnings per share	3,458,313	411,762
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Shares not included in computation of earnings per share	3,221,728	'

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Schedule of Liabilities Measured at Fair Value) (Details) (Recurring [Member], USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Derivative liabilities	'	$20,848	'
Level 1 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Derivative liabilities	'	'	'
Level 2 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Derivative liabilities	'	'	'
Level 3 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Derivative liabilities	'	$20,848	$37,334

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Schedule of Level 3 Fair Value Liabilities) (Details) (Recurring [Member], USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Balance	'	$20,848
Fair Value Measurements of Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Balance	20,848	37,334
Transfer in / (out) of Level 3	'	'
Adjustments resulting from a change in fair value of derivative liabilities	-20,848	-16,486
Balance	'	$20,848

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Inventories [Abstract]	'	'
Raw materials	$18,283	$28,533
Finished goods	11,420	10,679
Total Inventories	$29,703	$39,212

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Property and Equipment [Abstract]	'	'
Cryogenic shippers	$1,037,286	$962,565
Furniture and fixtures	30,746	30,746
Machinery and equipment	386,731	380,526
Leasehold improvements	30,913	30,913
Property and Equipment, gross	1,485,676	1,404,750
Less accumulated depreciation and amortization	-1,076,784	-899,265
Property and Equipment, net	408,892	505,485
Depreciation	$219,400	$281,700

Intangible_Assets_Schedule_of_

Intangible Assets (Schedule of Intagible Assets) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Amount	$701,341	$701,341
Accumulated Amortization	-521,255	-429,078
Net Amount	180,086	272,263
Amortization expense for intangible assets	92,200	112,300
Patents and trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Amount	154,214	154,214
Accumulated Amortization	-55,712	-54,251
Net Amount	98,502	99,963
Weighted Average Amortization Period (years)	'4 years 10 months 24 days	'5 years 10 months 24 days
Software development costs for internal use [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Amount	547,127	547,127
Accumulated Amortization	-465,543	-374,827
Net Amount	$81,584	$172,300
Weighted Average Amortization Period (years)	'1 year 7 months 6 days	'2 years 7 months 6 days

Intangible_Assets_Schedule_of_1

Intangible Assets (Schedule of Future Amortization of Intangible Assets) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Intangible Assets [Abstract]	'	'
2015	$62,884	'
2016	49,770	'
2017	28,199	'
2018	19,617	'
2019	19,616	'
Intangible assets, net	$180,086	$272,263

Accrued_Compensation_and_Relat2

Accrued Compensation and Related Expenses (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Accrued Compensation and Related Expenses [Abstract]	'	'
Accrued salary and wages	$80,328	$85,554
Accrued paid time off	155,166	92,376
Accrued board of director fees	214,553	38,000
Other accrued obligations	4,241	1,502
Total accrued compensation and related expenses	$454,288	$217,432

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Apr. 01, 2006
Related Party Transaction [Line Items]	'	'	'
Aggregate principal balances	$555,500	$651,500	'
Aggregate monthly principal payments	'	'	2,500
Increased in monthly principal payments	2,500	'	'
Maximum amount of aggregate monthly principal payment	10,000	'	'
Total aggregate principal payment	8,000	'	'
Maturity period of remaining unpaid principal and accrued interest	1-Mar-15	'	'
Related-party interest expense	36,500	42,200	'
Accrued interest payable	802,600	466,200	'
Interest rate	6.00%	'	'
Bridge Notes [Member] | Richard Rathmann [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Notes issued	100,000	'	'
5% Bridge Notes [Member] | Jerrell Shelton [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Notes issued	120,000	'	'
GBR Investments, LLC [Member] | Bridge Notes [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Notes issued	200,000	'	'
GBR Investments, LLC [Member] | 5% Bridge Notes [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Notes issued	$100,000	'	'

Convertible_Notes_Payable_Deta

Convertible Notes Payable (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

2 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Aug. 31, 2013

Aug. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Oct. 31, 2013

Aug. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Oct. 31, 2013

Jun. 13, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

2013 Bridge Note [Member]

2014 Bridge Note [Member]

2013 and 2014 Bridge Notes [Member]

2013 and 2014 Bridge Notes [Member]

2013 and 2014 Bridge Notes [Member]

2013 and 2014 Bridge Notes [Member]

2013 and 2014 Bridge Notes [Member]

2013 and 2014 Bridge Notes [Member]

Bridge Notes [Member]

Bridge Notes [Member]

Bridge Notes [Member]

Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

Maximum [Member]

Minimum [Member]

January 31 2013 [Member]

February 1 2013 [Member]

GBR Investments, LLC [Member]

GBR Investments, LLC [Member]

Emergent Financial Group, Inc. [Member]

Emergent Financial Group, Inc. [Member]

Emergent Financial Group, Inc. [Member]

Emergent Financial Group, Inc. [Member]

Emergent Financial Group, Inc. [Member]

Jerrell Shelton [Member]

Other Current Assets [Member]

Other Current Assets [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Principal amount

'

'

$1,294,500

$2,765,301

$4,059,801

'

'

'

'

'

'

'

'

'

$1,793,000

'

'

'

'

'

'

'

'

Interest rate during period

'

'

'

'

'

'

'

'

15.00%

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Due date

'

'

'

'

31-Dec-13

'

'

'

'

'

'

'

'

'

30-Jun-14

'

'

'

'

'

'

'

'

Accrued interest

'

'

'

'

0

9,900

'

'

'

'

'

'

'

'

14,100

'

'

'

'

'

'

'

'

Notes issued

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

100,000

'

'

'

'

'

'

120,000

Warrants issued to purchase shares

'

'

'

'

'

'

'

'

'

'

'

1,797,457

'

'

896,500

'

1,911,259

'

'

'

'

'

'

Exercise price

'

'

'

'

'

'

$0.19

$0.29

'

'

$0.37

'

'

'

$0.49

'

$0.20

'

'

'

'

'

'

Fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

199,200

'

'

279,100

'

'

'

'

'

'

'

'

Interest rate

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

5.00%

'

'

'

'

'

'

'

'

Debt conversion, principal and interest converted

4,127,201

'

'

'

'

'

'

'

'

'

4,127,202

'

'

'

'

'

'

1,743,000

'

'

'

'

'

Debt converstion, number of units issued

'

'

'

'

'

'

'

'

'

'

20,636,011

'

'

'

'

'

'

'

'

'

'

'

'

Debt conversion, conversion price

'

'

'

'

'

'

'

'

'

'

$0.20

'

'

'

$10.80

'

'

'

'

'

'

'

'

Debt conversion, converted units description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

(i) one share of common stock of the Company ("Common Stock") and (ii) one warrant to purchase one share of Common Stock at an exercise price of $0.37 per share

Warrants, exercisable date

'

'

'

'

'

'

'

'

'

'

31-Mar-14

'

'

'

31-May-14

'

'

'

'

'

'

'

'

Warrants expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-18

'

'

'

'

'

'

'

'

Debt conversion expense

13,713,767

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt interest expense

'

'

'

'

'

'

'

'

'

'

'

'

199,200

0

94,300

'

'

'

385,400

8,700

'

'

'

Percentage of Offering Price on Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

90.00%

'

'

'

'

Percentage of Commission on Principal Balance of Notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

'

'

'

'

Debt financing costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$375,900

$116,500

$98,400

$107,800

'

Derivative_Liabilities_Narrati

Derivative Liabilities (Narrative) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Derivative Liabilities [Abstract]	'	'
Derivative warrant liabilities	'	$20,848
Derivative gains	$20,848	$16,486

Derivative_Liabilities_Schedul

Derivative Liabilities (Schedule of Fair Value Assumptions for Derivative Liabilties) (Details) (Common Stock Purchase Warrant Liabilities [Member])	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Dividend yield	'	'
Minimum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Expected life (years)	'4 days	'1 year 4 days
Risk-free interest rate	0.03%	0.14%
Volatility	70.00%	129.00%
Maximum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Expected life (years)	'9 months 22 days	'1 year 9 months 22 days
Risk-free interest rate	0.15%	0.33%
Volatility	144.00%	158.00%

Commitments_and_Contingencies_1

Commitments and Contingencies (Narrative) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Property Subject to or Available for Operating Lease [Line Items]	'	'
Rental expense	$178,000	$204,000
Minimum amount of additional compensation	2,000,000	'
Consulting fees for services	$395,300	$401,100
Lake Forest Facility [Member]	'	'
Property Subject to or Available for Operating Lease [Line Items]	'	'
Area of lease	11,900	'
Minimum notice period to cancel lease	'120 days	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Schedule of Future Minimum Lease Payments) (Details) (USD $)	Mar. 31, 2014
Commitments and Contingencies [Abstract]	'
2015	$192,800
2016	26,700
Future minimum payments due	$219,500

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	2-May-14
			Subsequent Event [Member]
			Class A Preferred Stock [Member]
Stockholders' Equity [Abstract]	'	'	'
Common stock, shares authorized	250,000,000	250,000,000	'
Common stock, par value	$0.00	$0.00	'
Preferred stock, par value	$0.00	$0.00	$0.00
Class of Stock [Line Items]	'	'	'
Preferred stock, shares authorized	2,500,000	2,500,000	800,000

Stockholders_Equity_Schedule_o

Stockholders' Equity (Schedule of Common Stock Reserved for Future Issuance) (Details)	Mar. 31, 2014
Stockholders Equity [Line Items]	'
Common Stock Reserved for Future Issuance	73,088,548
Stock Options [Member]	'
Stockholders Equity [Line Items]	'
Common Stock Reserved for Future Issuance	11,894,205
Warrants [Member]	'
Stockholders Equity [Line Items]	'
Common Stock Reserved for Future Issuance	61,194,343

StockBased_Compensation_Narrat

Stock-Based Compensation (Narrative) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Sep. 30, 2009	Sep. 06, 2013	Sep. 13, 2012	Mar. 31, 2014	Sep. 30, 2011
			Warrants [Member]	Stock Options [Member]	Stock Incentive Plan 2002 [Member]	Plan 2009 [Member]	Plan 2009 [Member]	Plan 2011 [Member]	Plan 2011 [Member]	Plan 2011 [Member]	Plan 2011 [Member]
					Stock Options [Member]	Stock Options [Member]	Stock Options [Member]	Stock Options [Member]	Stock Options [Member]	Stock Options [Member]	Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Warrants outstanding	262,856	312,856	'	'	'	'	'	'	'	'	'
Total number of shares authorized	'	'	'	'	500,000	'	1,200,000	'	'	'	3,000,000
Additional shares authorized	'	'	'	'	'	'	'	7,100,000	3,000,000	'	'
Total shares available for future grant	'	'	'	'	0	299,741	'	'	'	7,405,004	'
Estimated forfeiture rate	'	'	'	0.00%	'	'	'	'	'	'	'
Intrinsic value per share	'	'	$0.52	$0.52	'	'	'	'	'	'	'
Unrecognized compensation cost related to unvested stock options	'	'	'	$1,600,000	'	'	'	'	'	'	'
Weighted average recognition period	'	'	'	'3 years	'	'	'	'	'	'	'

StockBased_Compensation_Summar

Stock-Based Compensation (Summary of Warrant Activity) (Details) (Warrants [Member], USD $)	12 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Warrants [Member]	'		'
Number of Shares	'		'
Outstanding	37,027,199		37,144,504
Issued	25,241,227		30,000
Exercised	-926,315		'
Forfeited	-39,728		-123,376
Expired	-108,040		-23,929
Outstanding	61,194,343		37,027,199
Weighted-Average Exercise Price/Share	'		'
Outstanding	$1.18		$1.18
Issued	$0.35		$0.50
Exercised	$0.22		'
Forfeited	$8.49		$0.77
Expired	$7.96		$8.89
Outstanding	$0.84		$1.18
Vested (exercisable) --March 31, 2014	$0.84		'
Weighted-Average Remaining Contractual Term (Years)	'		'
Outstanding --March 31, 2014	'2 years 10 months 24 days		'
Vested (exercisable) --March 31, 2014	'2 years 10 months 24 days		'
Aggregated Intrinsic Value	'		'
Outstanding --March 31, 2014	$3,987,500	[1]	'
Vested (exercisable) --March 31, 2014	$3,960,600		'
[1]	Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of the common stock on March 31, 2014, which was $0.52 per share.

StockBased_Compensation_Schedu

Stock-Based Compensation (Schedule of Warrants Outstanding and Exercisable) (Details) (Warrants [Member], USD $)	12 Months Ended
	Mar. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number Outstanding	61,194,343
Number Exercisable	60,297,010
$ 0.19 - $ 0.20 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$0.19
Exercise Price, maximum	$0.20
Number Outstanding	2,437,574
Weighted-Average Remaining Contractual Life (Years)	'4 years 3 months 18 days
Weighted-Average Exercise Price	$0.20
Number Exercisable	2,437,574
Weighted-Average Exercise Price	$0.20
$ 0.21 - $ 0.37 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$0.21
Exercise Price, maximum	$0.37
Number Outstanding	20,980,838
Weighted-Average Remaining Contractual Life (Years)	'4 years 6 months
Weighted-Average Exercise Price	$0.37
Number Exercisable	20,980,838
Weighted-Average Exercise Price	$0.37
$ 0.38 - $ 0.69 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$0.38
Exercise Price, maximum	$0.69
Number Outstanding	10,932,429
Weighted-Average Remaining Contractual Life (Years)	'3 years
Weighted-Average Exercise Price	$0.67
Number Exercisable	10,035,929
Weighted-Average Exercise Price	$0.69
$ 0.70 - $ 0.92 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$0.70
Exercise Price, maximum	$0.92
Number Outstanding	21,431,557
Weighted-Average Remaining Contractual Life (Years)	'1 year 8 months 12 days
Weighted-Average Exercise Price	$0.77
Number Exercisable	21,431,557
Weighted-Average Exercise Price	$0.77
$ 0.93 - $10.80 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$0.93
Exercise Price, maximum	$10.80
Number Outstanding	5,411,945
Weighted-Average Remaining Contractual Life (Years)	'10 months 24 days
Weighted-Average Exercise Price	$3.53
Number Exercisable	5,411,112
Weighted-Average Exercise Price	$3.53

StockBased_Compensation_Schedu1

Stock-Based Compensation (Schedule of Assumptions Used to Estimate Fair Value of Stock Options) (Details) (Stock Options [Member])	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate, minimum	0.19%	0.63%
Risk-free interest rate, maximum	1.84%	2.22%
Volatility, minimum	127.00%	124.00%
Volatility, maximum	140.00%	166.00%
Dividend yield	0.00%	0.00%
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life (years)	'1 year 7 months 6 days	'2 years 7 months 6 days
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life (years)	'6 years 7 days	'10 years

StockBased_Compensation_Summar1

Stock-Based Compensation (Summary of Stock Option Activity) (Details) (Stock Options [Member], USD $)	12 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
Stock Options [Member]	'		'
Number of Shares	'		'
Outstanding	5,095,741		1,355,132
Granted (weighted-average fair value of $0.26 and $0.24 per share)	7,673,272		4,063,109
Exercised	-657,000		'
Forfeited	-197,808		-322,500
Expired	-20,000		'
Outstanding	11,894,205		5,095,741
Vested (exercisable) --March 31, 2014	5,543,002		'
Unvested (unexercisable) --March 31, 2014	6,351,203		'
Weighted-Average Exercise Price/Share	'		'
Outstanding	$0.47		$1.14
Granted (weighted-average fair value of $0.26 and $0.24 per share)	$0.28		$0.29
Exercised	$0.20		'
Forfeited	$0.32		$0.98
Expired	$6		'
Outstanding	$0.35		$0.47
Vested (exercisable) --March 31, 2014	$0.42		'
Unvested (unexercisable) --March 31, 2014	$0.30		'
Weighted-Average Remaining Contractual Term (Years)	'		'
Outstanding --March 31, 2014	'8 years 7 months 6 days		'
Vested (exercisable) --March 31, 2014	'8 years		'
Unvested (unexercisable) --March 31, 2014	'3 years		'
Aggregated Intrinsic Value	'		'
Outstanding --March 31, 2014	$2,578,900	[1]	'
Vested (exercisable) --March 31, 2014	1,110,600		'
Unvested (unexercisable) --March 31, 2014	$1,468,300		'
Weighted-average fair value	$0.24		$0.26
[1]	Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of the common stock on March 31, 2014, which was $0.52 per share.

StockBased_Compensation_Schedu2

Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) (Stock Options [Member], USD $)	12 Months Ended
	Mar. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number Outstanding	11,894,205
Number Exercisable	5,543,002
$ 0.17 - $ 0.48 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$0.17
Exercise Price, maximum	$0.48
Number Outstanding	10,523,036
Weighted-Average Remaining Contractual Life (Years)	'8 years 10 months 24 days
Weighted-Average Exercise Price	$0.27
Number Exercisable	4,428,083
Weighted-Average Exercise Price	$0.27
$ 0.52 - $ 0.98 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$0.52
Exercise Price, maximum	$0.98
Number Outstanding	1,234,469
Weighted-Average Remaining Contractual Life (Years)	'6 years 3 months 18 days
Weighted-Average Exercise Price	$0.66
Number Exercisable	987,594
Weighted-Average Exercise Price	$0.66
$ 1.05 - $ 2.20 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$1.05
Exercise Price, maximum	$2.20
Number Outstanding	48,600
Weighted-Average Remaining Contractual Life (Years)	'6 years 4 months 24 days
Weighted-Average Exercise Price	$1.64
Number Exercisable	39,225
Weighted-Average Exercise Price	$1.69
$ 4.30 - $ 8.31 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Price, minimum	$4.30
Exercise Price, maximum	$8.31
Number Outstanding	88,100
Weighted-Average Remaining Contractual Life (Years)	'2 years 3 months 18 days
Weighted-Average Exercise Price	$4.74
Number Exercisable	88,100
Weighted-Average Exercise Price	$4.74

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014
Operating Loss Carryforwards [Line Items]	'
Net operating loss carryforwards, expiration	31-Dec-20
Federal [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net operating loss carryforwards	39,086,000
Federal [Member] | Research Tax Credit Carryforward [Member]	'
Operating Loss Carryforwards [Line Items]	'
Tax Credit Carryforward	18,000
Tax Credit Carryforward, Expiration Date	31-Dec-26
State [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net operating loss carryforwards	35,759,000
California [Member] | Research Tax Credit Carryforward [Member]	'
Operating Loss Carryforwards [Line Items]	'
Tax Credit Carryforward	64,000

Income_Taxes_Schedule_of_Defer

Income Taxes (Schedule of Deferred Tax Assets) (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Net operating loss carryforward	$15,379	$13,505
Research credits	60	51
Expenses recognized for granting of options and warrants	1,651	1,319
Accrued expenses and reserves	135	32
Valuation allowance	17,225	14,907
Total deferred tax assets	'	'

Income_Taxes_Schedule_of_Incom

Income Taxes (Schedule of Income Tax Provision) (Details) (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Taxes [Abstract]	'	'
Computed tax benefit at federal statutory rate	($6,650,000)	($2,169,000)
State tax, net of federal benefit	-327,000	-359,000
Warrant MTM Adjustment	-7,000	-6,000
Induced conversion costs	4,663,000	'
Interest expense	'	1,000
Permanent items and other	4,600	215,600
Valuation allowance	2,318,000	2,319,000
Total income tax provision	$1,600	$1,600

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2014	Mar. 31, 2013
Quarterly Financial Data (Unaudited) [Abstract]	'	'	'	'	'	'	'	'	'	'
Total revenues	$835,000	$757,000	$580,000	$488,000	$368,000	$307,000	$234,000	$191,000	$2,659,943	$1,100,539
Gross margin (loss)	143,000	167,000	72,000	55,000	-153,000	-62,000	-111,000	-163,000	436,955	-487,284
Operating loss	-1,274,000	-1,257,000	-1,287,000	-1,260,000	-1,681,000	-1,549,000	-1,554,000	-1,541,000	-5,078,375	-6,324,458
Net loss	($1,441,000)	($1,840,000)	($14,960,000)	($1,324,000)	($1,717,000)	($1,567,000)	($1,551,000)	($1,546,000)	($19,565,426)	($6,382,433)
Net loss per share, basic and diluted	($0.02)	($0.03)	($0.38)	($0.03)	($0.05)	($0.04)	($0.04)	($0.04)	($0.40)	($0.17)

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Jun. 13, 2014

29-May-14

29-May-14

29-May-14

Jun. 13, 2014

Jun. 13, 2014

Jun. 13, 2014

Jun. 13, 2014

29-May-14

2-May-14

Jun. 13, 2014

Jun. 13, 2014

5% Bridge Notes [Member]

5% Bridge Notes [Member]

Subscription Agreement [Member]

Subscription Agreement [Member]

Subscription Agreement [Member]

Class A Preferred Stock [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Emergent Financial Group, Inc. [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

5% Bridge Notes [Member]

Investors [Member]

Emergent Financial Group, Inc. [Member]

Subscription Agreement [Member]

Class A Preferred Stock [Member]

Class A Preferred Stock [Member]

Class A Preferred Stock [Member]

Jerrell W. Shelton and GBR Investments, LLC [Member]

Investors [Member]

Emergent Financial Group, Inc. [Member]

Emergent Financial Group, Inc. [Member]

5% Bridge Notes [Member]

Subscription Agreement [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

2,500,000

2,500,000

'

'

'

'

'

'

'

'

'

'

800,000

'

'

Preferred stock, par value

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

Preferred stock, dividends per share

'

'

'

'

'

'

'

'

'

'

'

'

$0.96

'

'

Preferred stock, preference payment per share

'

'

'

'

'

'

'

'

'

'

'

'

$12

'

'

Number of common stock shares issuable for preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

30

'

'

Conversion price per dividend

'

'

'

'

'

'

'

'

'

'

'

'

$0.40

'

'

Preferred stock, redemption price per share

'

'

'

'

'

'

'

'

'

'

'

'

$12

'

'

Preferred stock, liquidation preference per share

'

'

'

'

'

'

'

'

'

'

'

'

$12

'

'

Gross proceeds from issuance of preferred stock and warrants

'

'

'

'

'

'

'

'

$839,600

'

'

'

'

'

'

Net proceeds from issuance of preferred stock and warrants

'

'

'

'

'

'

'

'

628,700

'

'

'

'

'

'

Stock issued, shares

'

'

'

'

'

'

'

163,608

'

'

'

'

'

69,964

'

Warrants issued to purchase shares

'

'

896,500

'

'

'

'

1,308,864

'

'

'

'

'

559,712

'

Number of shares called by each warrant

'

'

'

'

'

'

3

'

'

'

'

'

'

'

8

Warrants expiration date

'

'

31-Dec-18

'

'

'

'

'

'

'

'

'

'

'

19-Mar-19

Exercise price of warrants

'

'

$0.49

'

'

'

$0.50

$0.50

'

'

'

'

'

$0.50

$0.50

Principal amount

'

'

1,793,000

'

'

'

'

'

'

'

'

'

'

'

'

Price per Unit

'

'

$12

'

'

'

'

'

'

'

'

'

'

'

'

Debt conversion, conversion price

'

'

$10.80

'

'

'

'

'

'

'

'

'

'

'

'

Debt conversion, principal and interest converted

4,127,201

'

'

1,743,000

220,000

'

'

'

'

'

'

'

'

'

'

Commission, percentage

'

'

'

'

'

3.00%

10.00%

'

'

'

'

'

'

'

'

Non-accountable finance fee, percentage

'

'

'

'

'

1.00%

3.00%

'

'

'

'

'

'

'

'

Legal expenses

'

'

'

'

'

'

'

'

'

'

'

$40,000

'

'

'

Preferred stock, shares outstanding

0

0

'

'

'

'

'

'

'

233,572

'

'

'

'

'

Warrants outstanding

262,856

312,856

'

'

'

'

'

'

'

1,868,576

638,646

'

'

'

'